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Abstract 
Toxoplasma gondii (T. gondii) is a widespread, obligate intracellular protozoan 
parasite with an exceptional ability to invade, survive and replicate within nearly all 
nucleated cells. It is responsible for toxoplasmosis in warm-blooded vertebrates. 
Although generally mild or asymptomatic for healthy people, toxoplasmosis may 
cause abortion or neonatal malformations if contracted during pregnancy. 
Furthermore, it is often lethal for immunocompromised patients and transplant 
recipients. Many studies have been focused on improvement of diagnostic testing 
for toxoplasmosis and development of subunit vaccines that could prevent or 
attenuate the disease. 
P30, a major surface antigen of T. gondii, is very abundant, conserved in most 
strains, and present both in the vesicular network of the parasitophorous vacuole and 
on the surface of the parasite. It is highly immunogenic and can stimulate 
organisms to elicit IgG, IgM, IgA antibodies and interferon y. Purified P30 has 
been tested as a single antigen for serodiagnosis of acute and chronic toxoplasmosis. 
Also, passive transfer of monoclonal anti-P30 antibody and active immunization with 
P30 antigen in liposomes suggested that P30 is a protective immunogen against 
toxoplasmosis. The gene encoding for P30 has been cloned and completely 
vi 
sequenced. Therefore, it would be valuable to produce large amount and high 
quality P30 by recombinant DNA technology for applications such as diagnostic 
reagent and potential subimit vaccine, and for study on its role in invasion. 
To test whether plants can be used as bioreactors to produce high quality T 
gondii surface antigen P30 in bulk amount, the gene encoding this antigen, under the 
control of constitutive or seed-specific promoter, had been introduced into tobacco. 
Successful integration oftransgenes into tobacco genome was confirmed by genomic 
PGR and Southern blot analysis. The presences of P30 transcripts were detected by 
RT-PCR and northern blot analysis. However, no recombinant P30 protein could be 
detected by SDS-PAGE and western blot analysis. Possible reasons for failure in 
P30 expression in plants may be sited at translation and/or posttranslation levels. 
Further studies are proposed and required to improve P30 translation efficiency and 
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Chapter 1 General Introduction 
The protozoan Toxoplasma gondii is a widespread, obligate intracellular parasite. 
It has an extremely broad host range and an exceptional ability to invade, survive and 
replicate within nearly all nucleated cells (Tomavo et al., 1992). Cats are the 
definitive hosts (Frenkel et al, 1970) and are important in transmission of T. gondii 
to human beings and other animals, which serve as intermediate hosts. The life 
cycle of T. gondii is complex with two major asexual stages and a flill sexual cycle 
(Dubey et al, 1998). 
T. gondii is responsible for toxoplasmosis in warm-blooded vertebrates. 
Approximately 30% of the world's human population is infected, although the 
prevalence varies markedly from country to country (Jackson and Hutchison, 1989). 
Generally mild or asymptomatic for healthy people, toxoplasmosis may cause 
abortion or neonatal malformations if contracted during pregnancy (Wong and 
Remington, 1994). Furthermore, it is often lethal for immunocompromised patients 
and transplant recipients (Frenkel, 1988). Many studies aim at improving 
diagnostic testing of toxoplasmosis and developing subunit vaccines that can prevent 
or attenuate the disease. 
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P30，also referred to as SAGl (surface antigen 1), is a major surface antigen of 
71 gondii. It is a stage-specific antigen since it can be detected only in tachyzoite 
(Kasper et al, 1984). It is very abundant (Santoro et al, 1985), conserved in most 
strains (Ware and Kasper, 1987), and highly immunogenic (Partanen et al” 1984; 
Khan et al” 1988). Besides its important role in immune mechanism, P30 also 
involves in the first stages of invasion (Kasper and Khan, 1993). 
With this information, it would be valuable to produce large amount and high 
quality of P30 by recombinant DNA technology, for production of diagnostic reagent 
and potential subunit vaccine, and for study on its role in invasion. A promising 
way to achieve this goal is to use plants as bioreactors or biochemical factories to the 
P30 protein. Using plants as bioreactors has the advantages including low cost, 
large quantity and high quality. 
In this study, the gene encoding the T. gondii major surface antigen P30 was 
used to construct chimeric genes under the control of different promoters. These 
chimeric genes were delivered into tobacco genome via Agrobacterium-m^6.\?Litd 
transformation and their expression analysed. The ultimate goal is to produce large 
amounts and high quality of P30 for vaccination or for other aspects of study and 
utilization. 
2 
Chapter 2 Literature Review 
2.1 Toxoplasma gondii 
Toxoplasma gondii is an obligate intracellular protozoan that belongs to the 
phylum Apicomplexa, class Sporozoa and subclass Coccidia. It is related to the 
parasites Plasmodium (the agents of malaria), Cryptosporidium, Eimeria, Isospora, 
Neospora and Sarcocystis. T. gondii has been recognized as one of the most 
common and successful parasites in the world by having an exceptional ability to 
invade, survive and replicate within nearly all nucleated cells of warm-blooded 
vertebrates (Tomavo et al., 1992). It is so-called Toxoplasma gondii because of the 
characteristic crescent shape of its active tachyzoite form (toxoplasma means 
arc-shaped in Greek) and the wild rodent (Ctenodactylus gondii) from which it was 
first discovered in North Africa (Baker, 1969). 
2.1.1 Morphology and Life Cycle of T. gondii 
The life cycle of Toxoplasma is very complex. Though it is common in many 
animals, including rodents, birds, sheep, swine, and cattle, cats are the definitive 
hosts of T. gondii (Frenkel et al., 1970). The sexual stage of T. gondii takes place 
only in the intestinal tract of cat (Figure 2- 1). 
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SEXUAL CYCLE ASEXUAL CYCLE 
^ , . ^ . Bradyzoites in 
Gut infection ^ 
tissue cysts 
，^ Ingestion ‘ ‘ 
Oocysts in feces • Tachyzoites 
Definitive Host Intermediate Host 
Figure 2- 1 The life cycle of J. gondii 
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There are three stages in a complete life cycle of T. gondii (Dubey et al,, 
1998): 
1) Tachyzoites in groups or clones 
The stage that multiplies rapidly in any cells of the intermediate host and in 
nonintestinal epithelial cells of the definitive host. Tachyzoites have also been 
termed endodyozoites or endozoites. They are often crescent shaped, 
approximately 2 by 6 jam, with a pointed anterior (conoidal) end and a rounded 
posterior end. 
2) Bradyzoites in tissue cysts 
The stage that multiplies slowly within a tissue cyst. Bradyzoites have also 
been called cystozoites. Tissue cysts containing bradyzoites vary in size from 
12 |Lim or less in diameter up to 100 |im or more. 
3) Sporozoites in oocysts 
The unsporulated oocysts are subspherical to spherical and are 10 by 12 jim in 
diameter while sporulated oocysts are subspherical to ellipsoidal and are 11 by 
13 |Lim in diameter. Spomlation occurs outside the cat within 1 to 5 days of 
excretion depending upon aeration and temperature. 
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Upon ingestion of tissue cysts, the cat's digestive enzymes lyse tissue cyst wall 
and the bradyzoites are released. Bradyzoites then penetrate the epithelial cells of 
small intestine where they undergo initial asexual multiplication. This is followed 
by the sexual cycle in which male and female gametes migrate into the gut and 
combine to form a zygote that develops into an immature oocyst. The oocyst, after 
being shed in the feces, will mature into an extraordinarily resistant entity containing 
8 sporozoites. Within 5 days the shed oocysts may sporulate and become infectious 
to other animals and humans. Sporulated oocysts are highly resistant to 
environmental conditions and can survive in moist shaded soil or sand for many 
months. 
After ingestion of oocysts by other animals, T. gondii may enter the blood and 
lymphatic systems where it multiplies asexually to form the rapidly dividing 
tachyzoite. Tachyzoite can invade virtually any cell in any tissue and continue to 
replicate in this life-stage. As the host's immune response rises to the challenge, the 
parasites encyst and differentiate to the very slowly dividing bradyzoites. Tissue 
cysts have a greater predilection for the central nervous system but are also found in 
heart and skeletal muscle. They may persist in infected host for life. However, 
ingestion of infected tissues by another mammal may result in infection being passed 
on by a mechanism similar to that of ingestion of oocysts. 
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2.1.2 Routes of Transmission 
Several routes of transmission are possible. T. gondii can be acquired by (1) 
ingestion of materials contaminated with infectious oocysts, (2) ingestion of tissue 
cysts contained in raw or undercooked meat from another intermediate host or (3) 
congenital transmission which occurs when a pregnant woman becomes infected and 
transmits the parasite to her fetus (Kasper and Boothroyd, 1993). 
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2.2 Toxoplasmosis 
Toxoplasmosis, a ubiquitous protozoan infection caused by T. gondii, was first 
observed in animals in 1908，and in humans in 1923. It exists all over the world 
and affects roughly 30% of the world's human population though the prevalence 
varies markedly from country to country (Jackson and Hutchison, 1989). About 
40% of US adults has serologic evidence of subclinical infection with T. gondii. In 
France and Germany, about 80% of the general population has serologic evidence of 
subclinical T. gondii infection (Sciammarella, 2001). In the past decade, T. gondii 
has received increased attention as a common but important opportunistic pathogen 
that affects up to 25% of AIDS patients. Many studies have been focused on how 
to improve diagnostic testing for toxoplasmosis and to develop subunit vaccines that 
can prevent or attenuate the disease. 
2.2.1 Influences and Symptoms 
Most cases of toxoplasmosis in immunocompetent hosts are subclinical or 
benign. However, severe complications may occur in two target groups listed 
below: 
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1) Pregnant women 
Women who contract T. gondii during pregnancy are most likely to pass it on to 
their unborn children through the placenta during later months of pregnancy 
(second and third trimester). If a fetus is infected with T. gondii during the 
early months of pregnancy (first trimester), the resulting complications are 
usually considerably more severe. Complications from infection of a fetus (in 
utero infection) include miscarriage or stillbirth. Some newborns are 
obviously ill with toxoplasmosis at birth. These babies may already have 
evidence of severe eye infections as well as a swollen liver or spleen, jaundice 
or pneumonia. Some of these babies die within days; those survive may have 
severe visual impairment, delayed development, mental retardation or seizures. 
Some babies seem healthy at birth but later reveal evidence of in utero infection, 
including hearing impairment, fluid accumulation in the brain (hydrocephalus), 
seizures, learning disabilities or mental retardation (Wong and Remington, 
1994). 
2) Immunosuppressed patients 
For immunosuppressed (e.g. organ transplant recipients and patients undergoing 
chemotherapy) or immunodeficient (AIDS) patients, toxoplasmosis is life 
threatening. Toxoplasmic encephalitis is one of the major opportunistic 
9 
infections of the central nervous system and the most frequent cause of focal 
brain lesions in patients. Symptoms can include severe headache, stiff neck, 
fever, delirium, muscle weakness, disturbed vision, clumsiness, speech 
impairment or seizures. Severe toxoplasmic pneumonia may also develop, 
with fever, shortness of breath and cough. Some patients have infection in the 
retina of the eye; others experience heart failure, irregularities of the heart's 
rhythm and rate, or swelling and inflammation of the sac surrounding the heart 
(Frenkel, 1988). 
2.2.2 Treatment of Toxoplasmosis 
2.2.2.1 Antitoxoplasma Drugs 
Only a few drugs are frequently used in toxoplasmosis treatment. These drugs 
are suggested to specifically inhibit the metabolisms of 7： gondii such as nucleic acid 
metabolism, protein synthesis or electron transfer system. However, none of them 
can completely eliminate T. gondii in the host and some of them may cause severe 
side effects in patients (Gross and Pohl，1996). Four well-established 
antitoxoplasma drugs are introduced below: 
1) Pyrimethamine 
Pyrimethamine affects nucleic acid metabolism by inhibiting dihydrofolate 
reductase in the conversion of hydrofolate to tetrahydrofolate. This reaction 
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occurs in both the host and parasite cells. Since dihydrofolate reductase of T. 
gondii possesses a significant higher affinity for pyrimethamine than that of the 
host cells, toxicity for T. gondii is more than 1000 times greater than that for the 
host cells. The combination of pyrimethamine with sulfadiazine, which acts 
synergistically, is currently the most effective therapy against tachyzoite stage 
of T. gondii. 
2) Sulfadiazine 
Sulfadiazine inhibits nucleic acid synthesis through inhibiting de novo folic acid 
synthesis in a competitive manner. It has been shown that sulfadiazine induces 
more severe side effects (such as hypersensitivity) than any other drugs 
currently used for toxoplasmosis. 
3) Clindamycin 
Through binding to ribosomes，clindamycin inhibits protein synthesis of T. 
gondii and results in reduction of the level of T. gondii replication. In the 
combination with pyrimethamine, clindamycin has received more attention in 
treatment of cerebral toxoplasmosis in immunosuppressed patients. 
4) Spiramycin 
Like clindamycin, spiramycin inhibits protein synthesis of T. gondii. With its 
exceptional persistence in the placenta, spiramycin is used in treatment of 
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women in their first months of pregnancy to prevent the spread of infection to 
their fetuses. 
2.2.2.2 Toxoplasma Vaccines 
Antitoxoplasma therapy can only target the multiplying and metabolically active 
form of T. gondii but not the non-multiplying or metabolically inactive one. With 
the intense and continuous use of antitoxoplasma drugs, parasite strains resistant to 
these drugs emerge, making treatment of toxoplasmosis even more difficult. 
Accompanying with severe side effects like antitoxoplasma agents, chemotherapy is 
not a satisfactory approach in fighting against T. gondii either. The emergence of T. 
gondii as a major opportunistic organism in immunocompromised individuals and 
the steady increase in economic losses due to animal toxoplasmosis have fuelled the 
interest in T, gondii vaccine development. Mutant strains of T. gondii have been 
employed in farming industry as the first commercial vaccine (Buxton, 1993). 
a) Mutant strains of T, gondii as vaccine 
In veterinary industry, toxoplasmosis is a major cause of economic loss through 
neonatal mortality, particularly in sheep, goats and pigs. The objectives of 
vaccination of farm animals are (1) to reduce abortions resulting from 
transplacental infection of fetuses and (2) to reduce the risk of human exposure 
resulting from ingestion of infected meat. To fulfill these purposes, 
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non-persistent strains of T. gondii are vaccine candidates. Several mutant 
strains of T. gondii were identified and promising results have been obtained in 
farming industry. 
1) Temperature-sensitive mutant TS-4 
TS-4 is a temperature-sensitive mutant tachyzoite. Because of its inability to 
live and divide at 37°C, it does not colonize the host's tissues nor form tissue 
cysts. McLeod et al. (1988) found that intraintestinal immunization of mice 
with mutant TS-4 was effective in reducing the incidence of congenital 
transmission. However, immunization does not prevent the formation of cysts 
by a challenge infection. 
2) S48 mutant 
S48 mutant is an incomplete tachyzoite with losing ability to develop tissue 
cysts. It is the first commercial vaccine used in sheep (Buxton, 1993). After 
subcutaneous injection into sheep, S48 mutant multiplies in local drainage 
lymph node and causes a febrile response between days 5 and 10. During this 
period, tachyzoites present in blood and antibody can be detected around day 11. 
Protection from one S48 mutant infection can last for 18 months. However, 
the problem of transmission cannot be solved and cyst burden seems to be 
unchanged in newborns of vaccinated animals. 
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3) T-263 mutant 
T-263 is a bradyzoite mutant that undergoes partial development in animal 
intestine and cannot produce oocysts. Therefore, it can prevent disease in cats 
and minimize oocyst shedding (Dubey, 1996). However, bradyzoites do not 
survive for more than a few hours at room temperature, so vaccine should be 
kept frozen throughout the manufacturing process, 
b) Subunit vaccine 
Due to the great risk of reversion to virulent form, vaccination with live, 
attenuated organisms in human is impractical. Development of subunit 
vaccines is thus an alternative way to achieve effective protection of humans 
against congenital infection and to prevent infection of immunosuppressed 
individuals. Antibodies in serum of infected hosts recognize a number of T. 
gondii tachyzoite antigens. Some of these antigens can be recognized by a 
specific class of immunoglobulins which signifying their potential use as 
subunit vaccines. 
Crude extract of T. gondii has been used to immunize mice in many studies. 
Bourguin et al (1993) demonstrated oral immunization with T. gondii sonicated 
in association with cholera toxin could protect mice from subsequent lethal oral 
infection. In addition, crude Toxoplasma extract could protect rats from 
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congenital toxoplasmosis (Zenner et al., 1999). However, the undefined 
composition of crude Toxoplasma extract made the results complicated and 
inconsistent, so preliminary fractionation of crude extract had been carried out. 
Partially purified antigens were fractionated by SDS-PAGE and tested by 
different immunoassays. A cytoplasmic antigen isolated by affinity 
chromatography with monoclonal antibody protected mice against lethal 
challenge with T. gondii (Sharma et al” 1984). Protective immunity was 
mediated by specific CD4+ T cell (Brinkmann et al,, 1993). In another studies 
by Lunden et al (1993), T. gondii major antigens (including P30，P22 and a 
glycoprotein with molecular weight of 6 kDa) incorporated into 
immunostimulating complexes (iscom) were used to immunize mice and the 
results showed that antigens in iscom could induce protective immune responses 
in mice against lethal interperitoneal and oral challenges. 
As antigens can induce protective immunity in the host, different methods 
were used to purify them as subunit vaccines. With the advances in molecular 
genetics, many surface and excreted/secreted antigen genes of T. gondii had 
been cloned and used in vaccine development. 
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2.3 Major T. gondii Surface Antigen - P30 
P30，also referred to as SAGl (surface antigen 1), is now recognized as a major 
surface antigen of T. gondii. It is a stage-specific antigen since it can be detected 
only in rapidly dividing and invasive tachyzoites and neither in bradyzoites of tissue 
cysts nor sporozoites from oocysts (Kasper et al., 1984). 
Biochemical analysis reveals that P30 has an apparent molecular weight of 30 
kDa under reducing conditions and approximately 27 kDa under non-reducing 
conditions (Kasper et al” 1983). As determined by radioimmunoassay, P30 is very 
abundant. It accounts for about 5% of the total tachyzoite protein (Santoro et al., 
1985). P30 is conserved in most strains (Ware and Kasper, 1987) and present both 
in vesicular network of the parasitophorous vacuole and on the surface of the parasite 
(Sibley et al” 1986). 
P30 is highly immunogenic and can stimulate organism to elicit IgG, IgM, IgA 
antibodies (Partanen et aL, 1984) and interferon y (Khan et al., 1988). Purified P30 
has been tested as a single antigen for serodiagnosis of acute and chronic 
toxoplasmosis. Protective role of P30 was first suggested by passive transfer of 
anti-P30 monoclonal antibody into mice (Johnson et al.’ 1983). Active 
immunization of P30 incorporated into liposomes also led to a nearly total protection 
of infected mice (Bulow and Boothroyd, 1991). These results indicate that P30 is 
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an appropriate antigen for development into a subunit vaccine for immunization of 
humans and domestic livestock. 
Besides its important role in immune mechanism, P30 also plays an important 
functional role in invasion. Both monoclonal and polyclonal monospecific P30 
antibodies inhibit infection of human fibroblasts and murine enterocytes. Fab 
fragments prepared from polyclonal, monospecific antibody to P30 also have 
inhibitory effect on invasion, indicating that this antibody directly blocks T. gondii 
infection of the host cells rather than agglutinating it. It is likely that there is a 
glycosylated host cell receptor to which P30 can bind (Kasper and Khan, 1993). 
The gene encoding P30 has been cloned and completely sequenced (Burg et al., 
1988). It contains no introns. Hybridization studies indicate that P30 is a single 
copy gene with mRNA of 1,500 nucleotides in length. Primary sequence of P30 
contains processing signals in its translated product. Firstly, it contains an 
NH2-tenninal signal sequence for entry into lumen of endoplasmic reticulum (ER) 
and secondly，it contains a glycosyl-phosphatidylinositol (GPI) signal sequence at 
COOH-terminal (Tomavo, 1996). One putative N-linked glycosylation site 
(Asn-Xxx-Ser/Thr) appears but is not used in T. gondii (Boothroyd et ah, 1998). 
With all the current understanding of P30，recombinant P30 protein had been 
produced in different expression systems. A fusion protein containing the mature 
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part of P30 supplied with six histidyl residues in the N-terminal end was expressed in 
Escherichia coli by Haming et al (1996). Recombinant protein purified on a 
Ni-chelate column could be recognized by T. go«(iz/-specific human IgG and IgM 
antibodies. Chen et al. (1991) expressed His-tagged P30 in an insect cell culture 
infected with recombinant baculovirus. Mice injected with recombinant protein 
produced specific humoral and cellular immune responses against Toxoplasma 
infection. Conformationally appropriate expression of P30 was also performed in 
CHO cells (Kim et al., 1994). Human sera reactive against Toxoplasma proteins 
could recognize purified recombinant P30 protein. Besides, P30 lacking GPI 
anchor was produced in the methylotrophic yeast, Pichia pastoris (Biemans et al., 
1998). Despite incomplete processing and unnatural glycosylation，anchor-less P30 
protein could be recognized by P30 specific monoclonal and human serum-derived 
antibodies and protected mice against a lethal challenge of T. gondii tachyzoites. 
Until now, many reports on P30 expression have been published, however, none of 
them is on plant expression systems. 
18 
2.4 Plants as Bioreactors 
During the past decade, significant advances have taken place in the field of 
plant molecular biology and plant biotechnology has also gained increasing scientific 
and economic importance all over the world. Many plant species can now be 
transformed through different methods and are even capable of producing very 
complex proteins such as antibodies and vaccines. A major commercial interest is 
currently focusing on the ability of transgenic plants to produce recombinant proteins 
in bulk amounts at relatively low cost, that is, to utilize plants as bioreactors. 
2.4.1 Advantages of Plant Bioreactors 
Using plant expression systems as bioreactors is attractive because it offers 
noteworthy advantages over other expression systems based on bacterial, microbial 
or animal cells. Firstly, the production and scale-up cost for plant expression 
system is lower than those for other systems. Due to plants' photoautotrophic 
nature, plant-based production requires only transgenic plants, sunlight, air, land, 
water，and fertilizers but not the dedicated equipment and expensive medium 
supplements. With modem agricultural practice, scale-up, harvesting, transporting, 
storage and processing of plants become easy and efficient (Fischer et al, 1999). 
Plant systems also take advantages in expressing eukaryotic genes, as nearly all of 
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the post-translational modifications essential for optimal biological activity of 
proteins are available. Furthermore, contamination of expressed proteins with 
human or animal pathogens or other infectious diseases will not occur in plants 
(Fischer and Emans, 2000). Stable integration of foreign genes into plant 
chromosomes and subsequent clonal expansion of transgenic plants can pass on the 
integrated foreign genes from generation to generation in a Mendelian fashion and if 
desired, homozygotes with increased levels of foreign gene expression can be 
selected (Arakawa et al, 1999). 
2.4.2 Plant-based Vaccines 
Vaccination has dramatically improved the quality of human health. Although 
vaccines are the most cost effective form of health care, however, their worldwide 
distribution is hampered, especially in developing countries. As plants can be 
engineered as novel biomanufacturing systems, it is possible to use plants as a source 
of “edible vaccines". This kind of vaccines is attractive as no cold storage or 
sophisticated expertise for their distribution is required (Fischer and Emans, 2000). 
Many studies have been carried out, demonstrating the potential utility of 
plant-derived subunit vaccine as the basis for vaccine development. 
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2.4.2.1 VP2 Capsid Protein of Mink Enteritis Virus 
Mink enteritis virus (MEV) is an autonomous paravovirus that infects mink. 
Its major clinical manifestation is a severe inflammation of intestine, resulting in 
profuse diarrhea. Infection of MEV can be controlled by vaccination. 
DNA sequence coding for a short linear epitope from the VP2 capsid protein of 
MEV was inserted into an infectious cDNA clone of cowpea mosaic virus (CMV). 
The construct was propagated in the black-eyed bean, Vigna unguiculata. As 
demonstrated by Dalsgaard et al. (1997), MEV epitope expressing on the surface of 
recombinant CMV conferred protection after subcutaneous injection in mink. 
2.4.2.2 Hepatitis B Surface Antigen 
Hepatitis B virus (HBV) infection is a major health problem in many 
developing countries. The discovery of surface antigen (HBsAg) enabled the 
development of HBV vaccine. 
In 1992, Mason et al transformed tobacco with the gene encoding HBsAg 
linked to a nominally constitutive cauliflower mosaic viral (CaMV) 35S promoter. 
Enzyme-linked immunoassays using a monoclonal antibody directed against human 
serum-derived HBsAg revealed the presence of recombinant HBsAg in extracts of 
transformed leaves. Spherical particles with an average diameter of 22 nm were 
observed in recombinant HBsAg purified from transgenic plants. Sedimentation of 
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transgenic plant extracts showed that recombinant HBsAg and human serum-derived 
HBsAg had similar physical properties. As recombinant HBsAg produced in 
transgenic plants is antigenically and physically similar to that derived from human 
serum and recombinant yeast, which are used as vaccines, Mason et al (1992) 
concluded that transgenic plants hold promise as low-cost vaccine production 
systems. 
2.4.2.3 Norwalk Virus Capsid Protein 
The capsid protein of Norwalk virus, a calicivirus causing epidemic acute 
gastroenteritis in humans, was expressed in transgenic tobacco and potato. Under 
the control of CaMV 35S promoter, recombinant Norwalk virus capsid protein 
(rNVCP) expression was up to 0.23% of total soluble protein in tobacco leaves. 
Mice treated with tobacco leaf extracts containing rNVCP developed both serum IgG 
and secretory IgA specific for rNVCP. Expression of rNVCP driven by paptatin 
(tuber-specific) promoter was about 0.37% of total soluble protein in potato tuber. 
When feeding mice directly with transgenic potato tubers, serum IgG specific for 
rNVCP was induced. These results also indicate the potential use of plants for 
production and delivery of edible vaccines (Mason et al., 1996). 
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2.5 Tobacco Expression System 
Tobacco, a leafy dicotyledonous plant with a fibrous root system, has served as 
a most useful plant material in pioneering research with special relevance to plant 
physiology and biochemistiy. It belongs to the Solanaceae family, also known as 
the potato or nightshade family, and to the genus Nicotiana, which was established 
by Linnaeus in 1753 (Tso, 1972). 
Tobacco is one of the most widely adopted model plant used in transgenic 
experiments primarily because it is readily transformed and subsequently regenerated 
into whole, fertile plants. Tobacco is normally growing as annual crop and is 
capable of self-fertilization to produce abundant seeds for analysis. 
2.5.1 Transformation Methods 
Tobacco plants can be transformed by different methods including 
Agrobacterium-mtdiidiXQd transformation and direct DNA uptake. 
2.5.1.1 Agrobactenum-m^d\2d^6^ Transformation 
The soil microorganism Agrobacterium is capable of transferring a discrete 
sequence of DNA called T-DNA from its tumor-inducing (Ti) plasmid into the 
genome of a broad range of gymnosperms and angiosperms. This natural ability of 
Agrobacterium to transform plants is exploited in the Agrobacterium-mQdiditQd 
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transformation method. 
Horsch et al (1985) developed a very simple leaf disk method for plant 
transformation. Basically, it involves immersion of leaf disks in a liquid culture of 
Agrobacterium carrying the chosen transformation vector; cocultivation of leaf disks 
with Agrobacterium; and the transfer of infected leaf disks to suitable medium for 
plant regeneration. 
2.5.1.2 Direct DNA Uptake 
Despite the fact that the host range of Agrobacterium is broad, a limitation to its 
use is that some crop species are recalcitrant to this mode of gene transfer. So more 
“direct DNA transfer" methods have been developed to tackle this problem. Direct 
DNA uptake is a physical process that does not require any biological vector, thus 
eliminating any possible host range problem mentioned above. 
Biolistic gene transfer (particle bombardment) involves the delivery of 
microprojectiles, usually of tungsten or gold coated with DNA, into plant cells by 
high-velocity acceleration. Both transient P-glucuronidase (GUS) expression (Seki 
et al., 1991a) and stable transformation (Seki et al., 1991b) of Arabidopsis 
demonstrated that it is feasible to transform plants via particle bombardment. 
Of different transformation systems, plant protoplast transformation is probably 
the one that necessitates the most finesse. Protoplasts are isolated either by a 
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mechanical or by an enzymatic process to remove the cell wall. Polyethylene 
glycol (PEG) is commonly used to facilitate DNA uptake into protoplasts of both 
dicots and monocots. In 1987, Negrutiu et al. established the protocol of 
PEG-mediated direct DNA uptake for tobacco. Electroporation can also be used to 
transform protoplasts. Pores generated on protoplast cell membrane through short 
electrical pulses of high electric field allow the entry of DNA into protoplasts 
electrophoretically (Jones, 1995). 
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2.6 Phaseolin and Its Regulatory Sequences 
Phaseolin is the predominant seed storage glycoprotein of French bean 
{Phaseolus vulgaris L.), constituting about 50% of the total protein in mature seeds. 
It is a globulin consisting of 3 subunit polypeptides, a，p and y, with apparent 
molecular weights of 53, 47 and 43 kDa, respectively (Sun et aL, 1981). The 3 
polypeptides are encoded by 16s mRNA species which are translated on polysomes 
attached to ER before entering the lumen of ER. The polypeptides are then 
glycosylated, folded into proper tertiary structure and assembled into a trimer. The 
trimer transits the Golgi apparatus and is finally deposited in membrane-bound 
vacuolar protein bodies 1-5 jam in diameter (Hoffman et al., 1988). 
Being spatially and temporally regulated, phaseolin is synthesized and 
accumulated rapidly only in the developing cotyledons, beginning when the 
cotyledons are about 7 mm in length and continuing until they reach 17-19 mm in 
length (Sun et al., 1978). 
(3-phaseolin gene was isolated from French bean by Sun et al. in 1981. It 
contains 80-base pair (bp) 5' untranslated region, 1,263-bp protein-encoding region 
interrupted by 5 intervening sequences, and 135-bp 3’ untranslated region. Since 
phaseolin is an abundant seed storage protein, representing 50% of the total protein 
in mature French bean, phaseolin promoter is a good candidate for expressing 
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recombinant proteins in transgenic plants. Under the control of phaseolin promoter, 
a chimeric gene encoding the Brazil nut methionine-rich protein was transformed 
into tobacco (Altenbach et al., 1989) and a significant increase (up to 30%) in 
methionine content of the transgenic tobacco seeds was observed. 
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Chapter 3 Expression of P30 in Transgenic Tobacco 
3.1 Introduction 
Chimeric genes encoding the major surface antigen P30 of T. gondii under the 
control of either constitutive or seed-specific promoter were constructed and 
transformed into tobacco. All the coding sequences contain a hexa-histidine tag 
(His-tag) and an enterokinase (EK) recognition site at the 5'end of the P30 gene for 
recombinant protein detection and purification. 
The P30 protein is expected to appear in all parts of the transgenic plants 
harboring the chimeric gene driven either by the CaMV 35S or the maize ubiquitin 1 
(Ubi) constitutive promoter. Transgenic plants containing the P30 gene under the 
regulation of seed-specific phaseolin promoter are expected to have their P30 protein 
present in the seed cytosol while those with the phaseolin signal peptide (Phas SP) 
would have their P30 accumulated in protein bodies. 
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3.2 Materials and Methods 
3.2.1 Chemicals 
Most chemicals used were of reagent grade or molecular grade and were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA) or otherwise 
noted. Restriction enzymes and other modifying enzymes for molecular biology 
experiments were obtained from New England Biolabs Inc. (Beverly, MA, USA) and 
Promega Biosciences (Madison, WI, USA) unless specified. 
3.2.2 Oligos: Primers and Adapters 
Oligos listed in Table 3- 1 were supplied by Integrated DNA Technologies, Inc. 
(Coralville, lA，USA). 
Adapters were prepared by mixing 100 pmole of each concerning oligo and 
allowing them to anneal as follows: 88�C for 2 minutes, 65°C for 10 minutes, 37°C 
for 10 minutes and then 25°C for 5 minutes. Phosphorylation of the annealed 
adapters was performed with 1 mM ATP and 10 units of T4 polynucleotide kinase 
(Promega) in IX T4 polynucleotide kinase buffer at 3 7 � C for 30 minutes. 
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Table 3- 1 Sequences of oligos used in this study 
Name of 
oligo DNA Sequence (5' to 3，） Purpose 
P30-5' CCCACTCTTGCGTACTACCCCA PCR screening  
of P3Q clones 
PGR screening 
of P30 clones; 
P30-3' CTTGATCGTTAGCGTGGCACCC Synthesis of 
DIG-labeled 
DNA Probe 
5 'P30-PCR TCTAGAATTCATGCACCATCATCATCATCATGAC PCR screening  
of P3Q clones 
3'P30-PCR ATACAAGCTTTCACCCGGCAAACTCCAGTTTC P^R screening  
of P30 clones 
P30-5，mid GTGACAGTACAAGCCAGAGCCT Sequencing “ 
P30-3，mid GAGTGCTGTCTGCACCGTAGG Sequencing 
P30-1D T A T G C C A C T T C A C T C C A C C A T C A T C A T C A T C A T C C A Generation of 
P30-D adapter 
P 3 0 2 D G A T C T G G A T G A T G A T G A T G A T G G T G G A G T G A A G T G G Generation of 
- ^ P3Q-D adapter 
P30-1E' TATGGTACCGTCTACATGCACCATCATCATCATCAT Generation of 
GACGACGACGACAAGGC P3Q-E adapter 
P30-2E' CATGGCCTTGTCGTCGTCGTCATGATGATGATGATG Generation of 
GTGCATGTAGACGGTACCA P30-E adapter 
P30-1F GGGTGAGTATACGGATCCA Generation of 
P30-F adapter 
P30-2F AGCTTGGATCCGTATACTCACCCTGCA Generation of 
|P30-F adapter 
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3.2.3 Plant Materials 
Seeds of wild type tobacco {Nicotiana tabacum var. xanthi N.C.) were surface 
sterilized in 100% Clorox (5.25% sodium hypochlorite) for 3 minutes with vigorous 
shaking, followed by washing with sterilized distilled water 3 times, each for 1 
minute. Sterilized seeds were allowed to germinate on MS agar [4.3 g/L Murashige 
& Skoog salts (Gibco)，2% sucrose, IX vitamin B5 and 0.8% bacto-agar, pH5.7] and 
grow at 25°C with an 18-hour photoperiod. Tobacco leaves about one-month old 
were used for Agrobacterium-mQ6\2iiQd transformation. After transformation, 
regenerated transgenic tobacco plants were transferred to soil and greenhouse for 
seed formation and subsequent analysis. 
3.2.4 Bacterial Strains 
Escherichia coli strain DH5a was used as a host for plasmid manipulation and 
maintenance. Agrobacterium tumefaciens strain LBA4404 containing the helper Ti 
plasmid pAL4404 was used in tobacco transformation. 
3.2.5 Construction of Chimeric Genes 
The original P30 coding sequence was isolated by Chen et al (1994) from T. 
gondii strain ZSl using polymerase chain reaction (PGR) technique. It was then 
modified by Wong and Lo (Chinese Univ., Hong Kong) to have the 5' signal peptide 
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(SP) and the 3，glycosyl-phosphatidyl inositol (GPI) signal sequence removed. The 
modified P30 cDNA was then subcloned into the bacterial expression vector 
pET30a(+) (Novagen) to form pET-ASP30APL 
In this study, the overall strategy for construction of chimeric genes was first to 
add coding sequences for His-tag and EK recognition site at the 5' end of the P30 
gene and to create suitable restriction sites for cloning with the use of adapters (Table 
3- 1 & Figure 3- 1). The modified P30 gene was then subcloned into a vector 
containing either the CaMV 35S，Ubi or phaseolin (with or without SP) promoter. 
Finally, the resulting cassettes with the P30 gene sandwiched between a promoter 
and a terminator were inserted into the Agrobacterium binary vector pBI121 for 
tobacco transformation. 
3.2.5.1 Modification of pET-ASP30API 
In the presence of adapters, pET-ASP30API carrying the P30 cDNA with its SP 
and GPI anchor removed was first modified to facilitate further cloning. 
As shown in Figure 3- 2, pET/P30F was constructed by inserting adapter P30-F 
(Figure 3- 1) in between the PstI and Hindlll sites of pET-ASP30APL Through this 
modification, a stop codon (TGA) and an AccI and BamHI sites were added at the 3， 
end of the P30 cDNA. 
For construction of pET/DP30F (Figure 3- 3), pET/P30F was first cut with Ndel 
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and Bglll. With addition of adapter P30-D (Figure 3- 1) in between the Ndel and 
Bglll sites of pET/P30F, pET/DP30F emerged with sequences coding for 4 additional 
amino acids (Ala, Thr, Ser and Leu) at the end of the phaseolin SP, a His-tag and an 
EK site at the 5' end of the P30 cDNA. The pET/DP30F was then used to construct 
of chimeric gene with the phaseolin promoter and phaseolin SP. 
With insertion of adapter P30-E' (Figure 3- 1) at the Ndel and Ncol sites of 
pET/P30F, pET/E’P30F was formed (Figure 3- 4). The pET/ET30F, with its Kpnl, 
AccI, start codon (ATG), His-tag and EK sites at the 5' end of the P30 cDNA, was 





5 ‘ r^GG TGA \GT\AT Ad |G| GATC d \A\ 
3 ' ACGTQCC ACT CA TA|TG C CTAG\G TTCGA 
PstI AccI BamHI Hindlll 
Adapter P30-D 
a. a. for Phas SP 
Ala Thr Ser Leu His-tag 
5 ' I TATdCC ACT TCA CTC CAC CAT CAT CAT CAT CAT CCl^ 




5 ‘ || M中 I GTAC\ d \GT\CT AA ATG CAC CAT CAT CAT CAT CAT 
3 ' I ACP CATG G||CA GA \ TG\ TAG GTG GTA GTA GTA GTA GTA 
Ndel Kpnl AccI 
EK site 
Asp Asp Asp Asp Lys 
GAC GAC GAC GAC AAG G|C| 
CTG CTG CTG CTG TTC CGGTAC\ 
Ncol 
Figure 3- 1 Adapters for modification of pET-ASP30API 
Start (ATG) and stop (TGA) codons are shaded. His-tag coding 
sequence is bolded and the sequences encoding 4 additional amino 
acids in the phaseolin SP in adapter P30-D and EK site in adapter 
P30-E' are underlined. 
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Ndel Bglll Kpnl Ncol PstI Hindlll  
• J I 
His-tag S-tag • • EK P30 His-tag — ^ 
pET-ASP30API 
V J 
PstI & Hindlll 
T 
Adapter P30-F • 
AccI BamHI 
Ndel Bglll Kpnl Ncol Pstl^ ^Hindlll 
His-tag S-tag • • EK P30 His-tag — ^ 
pET/P30F 
V > 
Figure 3- 2 Construction of chimeric gene pET/P30F 
Adapter P30-F was inserted in between the PstI and Hindlll sites of 
pET-ASP30APL The resulting construct, pET/P30F, contains a stop 
codon and an AccI and a BamHI sites at the 3, end of the P30 gene. 
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Ndel Bglll Ncol AccI BamHI 
• ! ! • 
His-tag S-tag • • EK P30 His-tag ~ ^ 
pET/P30F 
V / 
Ndel & Bglll • 
Adapter P30-D 
T 
Ndel Bglll Ncol AccI BamHI 
J 1 I r — J — — r t — — 1 
广 Phas SP I His-tag • EK P30 His-tag — ^ 
pET/DP30F 
\ > 
Figure 3- 3 Construction of chimeric gene pET/DP30F 
With insertion of adapter P30-D in between Ndel and Bglll of 
pET/P30F, pET/DP30F was constructed with sequences encoding 4 
additional amino acids in the phaseolin SP, a His-tag and an EK site at 
the 5' end of the P30 cDNA. 
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Ndel Bglll Ncol AccI BamHI 
JUL  
His-tag S-tag - - EK P30 His-tag — 
pET/P30F 
V J 
Ndel & Ncol 
Adapter P30-E， 
T 
Ndel Kpnl AccI Ncol AccI BamHI 
h ^ 1 ~ I — — r t — — I 
广 I ATG His-tag I EK P30 His-tag «««^ 
pET/E，P30F 
V > 
Figure 3- 4 Construction of chimeric gene pET/E'P30F 
With addition of adapter P30-E' at the Ndel and Ncol sites of 
pET/P30F, pET/E'P30F was constructed with sequences encoding a 
start codon, a His-tag and an EK site at the 5' end of the P30 cDNA. 
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3.2.5.2 Cloning of P30 into Vectors with Different Promoters 
Promoters used in this study can be divided into 2 categories: 
a) Constitutive promoter — The CaMV 35S & Ubi promoters; 
b) Seed-specific promoter - The phaseolin promoter with or without phaseolin 
SP. 
3.2.5.2.1 Cloning of P30 into Vector with CaMV 35S Promoter 
The P30 gene from pET/E'P30F was subcloned into pUC/35S, a vector with the 
CaMV 35S promoter (pro) and the nopaline synthase (Nos) terminator (ter), through 
insertion between the Kpnl and BamHI sites as illustrated in Figure 3-5，resulting in 
pUC/35S-HR 
3.2.5.2.2 Cloning ofP30 into Vector with Maize Ubiquitin 1 Promoter 
pUC/Ubi-HP, with its P30 cDNA regulated by the Ubi promoter and Nos 
terminator, was constructed using the same strategy as pUC/35S-HP (Figure 3- 6). 
3.2.5.2.3 Cloning of P30 into Vector with Phaseolin Promoter 
As shown in Figure 3- 7, the P30 insert in pET/E'P30F was excised using AccI 
and subcloned into pTZ/Phas (the vector containing the phaseolin promoter and 
phaseolin terminator) to form pTZ/Phas-HP. 
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3.2.5.2.4 Cloning of P30 into Vector with Phaseolin Promoter and Phaseolin SP 
The P30 gene was excised from pET/DP30F and subcloned into pBK/Phas.SP 
between the Ndel and AccI sites. The resulting construct, pBK/Phas.SP-HP, 
contained the phaseolin promoter and phaseolin SP (Figure 3-8). 
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Kpnl AccI AccI BamHI Hindlll Kpnl BamHI Hindlll 
F _ ATG His-tag EK P30 TGA _ � 广 35S pro GFP Nos ter � 
pET/E'P30F pUC/35S-GFP 
V / V / 
Kpnl & BamHI 
T t 
Hindlll Kpnl BamHI Hindlll 
KP作I B腿H I ( 35S pro Nos ter - v 
ATG His-tag EK P30 TGA pUC/35S 
\ / 
Ligation • 
Hindlll Kpnl BamHI Hindlll 
广 35S pro ATG His-tag EK P30 TGA Nos ter - v 
pUC/35S-HP 
V 办 
Figure 3- 5 Construction of chimeric gene pUC/35S-HP 
The P30 gene from pET/E，P30F was subcloned into pUC/35S-GFP 
between the Kpnl and BamHI sites. The resulting construct, 
pUC/35S-HP, contained the P30 gene sandwiched between the CaMV 
35S promoter and Nos terminator. (GFP = green fluorescent protein) 
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Kpnl AccI AccI BamHI Hindlll Kpnl BamHI Hindfll 
• - ATG His-tag EK P30 TGA _ � 广 Ubi pro GFP Nos ter 
pET/E'P30F pUC/Ubi-GFP 
V / V / 
Kpnl & BamHI 
T T 
Hindlll Kpnl BamHI Hindlll 
Kpnl B腿H I 广 Ubi pro Nos ter "V 
ATG His-tag EK P30 TGA pUC/Ubi 
V / 
Ligation • 
Hindlll Kpnl BamHI Hindlll 
广 Ubi pro ATG His-tag EK | P30 TGA NOS ter "V 
pUC/Ubi-HP 
V / 
Figure 3- 6 Construction of chimeric gene pUC/Ubi-HP 
The P30 gene from pET/E'P30F was subcloned into pUC/Ubi-GFP 
between the Kpnl and BamHI sites. The resulting construct, 
pUC/Ubi-HP, contained the P30 gene sandwiched between the Ubi 
promoter and Nos terminator. (GFP = green fluorescent protein) 
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Kpnl AccI /icc/BamHI Hindlll AccI AccI Hindlll 




Hindlll AccI AccI Hindlll 
dec/ AccI 广 Phas pro Phas ter 
ATG His-tag EK P30 TGA pTZ/PhaS 
(AccI) 
V J 
l _ I 
Ligation 
• 
Hindlll AccI AccI Hindlll 
f Phas pro ATG His-tag EK P30 TGA Phas ter � 
pTZ/Phas-HP 
V > 
Figure 3- 7 Construction of chimeric gene pTZ/Phas-HP 
The P30 insert was excised from pET/E'P30F using AccI and 
subcloned into pTZ/Phas. The resulting construct, pTZ/Phas-HP, 
contained the phaseolin (Phas) promoter and terminator flanking the 
P30 gene. 
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Ndel AccI Hindlll Ndel AccI Hindlll 
Phas SP His-tag EK P30 TGA , Phas pro | Phas S p " Phas Phas ter � 
pET/DP30F pBK/Phas.SP 
V / V ) 
Ndel & AccI 
• T 
Hindlll Ndel AccI Hindlll 
Ndel AccI . Phas pro Phas SP Phas Phas ter � 
PhasSP His-tag EK P30 TGA pBK/PhaS.SP 
(Ndel & AccI) 
V / 
Ligation 
Hindlll Ndel AccI Hindlll  
广 Phas pro Phas SP His-tag EK P30 TGA Phas ter 
pBK/Phas.SP-HP 
V > 
Figure 3- 8 Construction of chimeric gene pBK/Phas.SP-HP 
The P30 gene was excised from pET/DP30F and subcloned into 
pBK/Phas.SP through insertion between the Ndel and AccI sites. 
The resulting construct, pBK/Phas.SP-HP, contained the P30 gene 
sandwiched between the phaseolin (Phas) promoter with SP (signal 
peptide) and terminator. 
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3.2.5.3 Cloning of P30 into Agrobacterium Binary Vector pBI121 
Four chimeric P30 constructs, the pUC/35S-HP, pUC/Ubi-HP, pTZ/Phas-HP 
and pBK/Phas.SP-HP, were cut with Hindlll to release the promoter-P30-terminator 
cassettes. These cassettes were then inserted into the Hindlll site of Agrobacterium 
binary vector pBI121 (Clontech). The resulting constructs (Figure 3- 9)，containing 
the promoter-P3 0-terminator cassette sandwiched between neomycin 
phosphotransferase II (NPTII) selectable marker and P-glucuronidase (GUS) reporter 
genes, were transformed into Agrobacterium tumefaciens LBA4404 with the helper 
Ti plasmid pAL4404 by electroporation. The nucleotide and amino acid sequences 
of P30 in pBI/35S-HP, pBI/Ubi-HP and pBI/Phas-HP were illustrated in Figures 3-
10 and 3- 12 while those of pBI/Phas.SP-HP were shown in Figures 3- 11 and 3- 13. 
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35S pro His-tag EK | P30一 Nos ter pBI/35S-HP 
Ubi pro His-tag EK P30 Nos ter pBI/Ubi-HP 
Phas pro His-tag EK | P30一 Phas ter pBI/Phas-HP 
Phas pro Phas SP His-tag EK | P30一 Phas ter pBI/Phas.SP-HP 
‘ — — I — — ‘ 
RB Hindlll LB 
Nos pro NPTII Nos ter 35S pro GUS Nos ter 
pBI121 
V J 
Figure 3- 9 Cloning of chimeric P30 genes into Agrobacterium binary vector 
p B i m 
The promoter-P3O-terminator cassette was excised from pUC/35S-HP, 
pUC/Ubi-HP, pTZ/Phas-HP or pBK/Phas.SP-HP using Hindlll and 
inserted into the Hindlll site of Agrobacterium binary vector pBI121. 















Figure 3- 10 Nucleotide sequence of the P30 gene in pBI/35S-HP, pBIAJbi-HP 
or pBI/Phas-HP 
The length of the P30 gene in pBI/35S-HP, pBI/Ubi-HP or 
pBI/Phas-HP is 735 bp. The start (ATG) and stop (TGA) codons are 
shaded. A His-tag coding sequence (bolded) and an EK recognition 



















Figure 3 -11 Nucleotide sequence of the P30 gene in pBI/Phas.SP-HP 
The length of the P30 gene in pBI/Phas.SP-HP is 828 bp. The start 
(ATG) and stop (TGA) codons are shaded. The sequence of 
phaseolin SP is in lower case and an arrow indicates the possible SP 
cleavage site. The His-tag coding sequence is bolded and the EK 
recognition sequence is underlined. 
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MHHHHHHDDDDKAMGFTLKCPKTALTEPPTLAYSPNRQICPAGTTSSCTSKAVTLSS 




Figure 3-12 Deduced amino acid sequence of P30 in pBI/35S-HP, pBI/Ubi-HP 
or pBI/Phas-HP 
The P30 protein from pBI/35S-HP, pBI/Ubi-HP or pBI/Phas-HP is 
predicted to contain 244 amino acids. The His-tag is bolded while 







Figure 3- 13 Deduced amino acid sequence of P30 in pBI/Phas.SP-HP 
The P30 protein from pBI/Phas.SP-HP is predicted to contain 275 
amino acids before the cleavage of the phaseolin SP (in lower case). 
An arrow indicates the possible site for SP cleavage. The mature 
peptide should have 253 amino acids. The His-tag is bolded while 
the EK recognition site is underlined. 
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3.2.6 Transformation of Agrohacterium by Electroporation 
Plasmids, pBI/35S-HP, pBIAJbi-HP, pBI/Phas-HP, pBI/Phas.SP-HP and pBI121 
(the vector-alone control) were transformed into Agrobacterium tumefaciens 
LBA4404 with the helper Ti plasmid pAL4404 by electroporation. 
For each construct, an aliquot of 40 |LI1 of A. tumefaciens LBA4404 competent 
cells was thawed on ice, mixed with 10 ng of plasmid DNA and kept on ice for 1 
minute. The cell-DNA mix was then transferred to the bottom of a pre-chilled 0.2 
cm electroporation cuvette (Bio-Rad) and subjected to a pulse of 25 |LIF, 2.5 kV and 
600 ohms in the Gene Pulser (Bio-Rad). After discharge, one ml of SOC medium 
[2% bacto-tryptone, 0.5% bacto-yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgS04 and 20 mM glucose] was immediately added to the cuvette to 
rescue the cells. The cell suspension was then transferred to a 10 ml polypropylene 
tube and shaken at 28�C for 2 hours. The recovered culture was spread on LB agar 
plates supplemented with 50 mg/L kanamycin (Kan) and 25 mg/L streptomycin and 
allowed to grow at 28°C for 2-3 days. 
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3.2.7 Transformation, Selection and Regeneration of Tobacco 
Transformation of tobacco was carried out as described by Lin et al (1994) with 
modifications. A single colony of A. tumefaciens LBA4404 harboring the pBI121, 
pBI/Phas-HP, pBI/Phas.SP-HP, pBI/35S-HP or pBI/Ubi-HP was cultured in 3 ml of 
LB medium [10 g/L bacto-tryptone, 5 g/L bacto-yeast extract and 10 g/L NaCl: 
containing 50 mg/L Kan and 25 mg/L streptomycin at 30°C with shaking for 16 
hours. This 3-ml starter culture was then subcultured in 300 ml of YM broth [0.4 
g/L autolyzed, low sodium yeast extract, 10 g/L mannitol, 0.1 g/L NaCl，0.5 g/L 
K2HPO4 and 0.2 g/L MgS04®7H20] supplemented with 50 mg/L Kan and 25 mg/L 
streptomycin and allowed to grow at 30°C with shaking until its optical density 620 
nm (OD620) reached 0.8-1.0 (5 x 10^ cells/ml for 1 OD620). The cells were 
centrifiiged at 7,000 rpm for 10 minutes and the pellets were resuspended in MS 
medium with 0.5 mg/L MES to a concentration of cells/ml. 
Young tobacco leaves from one-month-old plants were removed and cut into 
small pieces (about 1 cm x 1 cm square disks). The explants were incubated with 
Agrobacterium cells for 10 minutes, transferred to solid MS medium with lower side 
facing up and incubated for 2 days at 25°C, using an 18 hour light/ 6 hour dark cycle. 
After cocultivation, the explants were transferred to shoot regeneration medium [MS 
agar plus 0.5% N^-benzyladenine (BA), 500 mg/L carbenicillin (Car) and 100 mg/L 
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Kan] and incubated at 25°C, using an 18 hour light/ 6 hour dark cycle until the 
formation of green calli and shoots. For root regeneration, the regenerated shoots 
were transferred to MS agar containing 500 mg/L Car and 100 mg/L Kan in Magenta 
boxes. Transgenic tobacco plants were finally transferred to soil in pots and 
allowed to grow in greenhouse. 
3.2.8 GUS Assay 
GUS assay was performed as described by Jefferson et al (1987). 
Regenerated tobacco leaves was soaked in GUS staining solution [100 mM sodium 
phosphate buffer, pH 7.0, 0.1% Triton X-100, 1 mM EDTA，0.5 mM K3.Fe(CN)6， 
0.05 mM K>Fe(CN)6 and 0.5 mg/ml X-glucuronide (X-gluc)] at 37°C overnight for 
color development. Chlorophyll background was removed by soaking in 70% 
ethanol (EtOH). 
3.2.9 Synthesis of Single-stranded DIG-labeled DNA Probe 
Anti-sense DIG-labeled P30 DNA probe was synthesized by PGR technique. 
A P30 fragment, serving as template for PGR, was excised from pET/E'P30F (Figure 
3- 4) by Kpnl and Hindlll double digestion and recovered with the QIAquick Gel 
Extraction Kit (QIAGEN). A 100 reaction mix containing 50 ng of the P30 
template, IX PGR buffer, 1 mM MgCl�，20 |LIM DIG dNTPs (Roche), 0.1 |LIM P30-3' 
primer (Table 3- 1), and 5 units of Platinum Taq DNA polymerase (Gibco) was 
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prepared for PCR reaction with the following conditions: 94°C for 10 minutes, 60 
cycles of 9 4 � C for 20 seconds, 65°C for 30 seconds and I T C for 1 minute, followed 
by 1 cycle of 72°C for 10 minutes. The labeling efficiency of the probe was 
estimated by a spot test using DIG-labeled control DNA as described in the manual 
for DIG DNA Labeling Kit (Roche). 
3.2.10 Extraction of Genomic DNA from Leaves 
Leaf genomic DNA was isolated by the Cetyltrimethylammonium bromide 
(CTAB) method (Doyle et al., 1990). Three pieces of leaf discs (cut by pressing 
tobacco leaf against the cap of an 1.5 ml microcentrifuge tube) were ground in 600 jul 
of 2% CTAB buffer [0.1 M Tris-HCl, pH 8.0，1.4 M NaCl, 20 mM EDTA, 2% CTAB 
and 0.2% P-mercaptoethanol (P-mer)] with a glass rod in the presence of sterile sand. 
The homogenate was incubated at 60°C for 40 minutes with periodic mixing. Half 
an ml of chloroform/ isoamyl alcohol (24:1, v/v) was added, mixed, and centrifuged 
at 14,000 rpm at 4°C for 15 minutes. The upper aqueous layer was transferred to a 
new tube and mixed with 500 ]x\ of cold isopropanol. The mixture was kept at 
-20°C for 1 hour and then centrifliged at 14,000 rpm at 4°C for 30 minutes. The 
pellet was washed with 70% EtOH. Dried pellet was dissolved in 50 jul of TE [10 
mM Tris-HCl, pH 8.0 and 1 mM EDTA] and quantified by OD260. 
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3.2.11 PCR of Genomic DNA with P30 Specific Primers 
PCR was performed to detect the presence of the P30 transgene in regenerated 
tobacco. A 25 )al reaction mix containing 500 ng of genomic DNA, IX PCR buffer, 
2 mM MgCl2, 0.2 mM dNTPs, 1 jiM P30-5' and P30-3，primers (Table 3- 1) and 1 
unit of Platinum Taq DNA polymerase (Gibco) was prepared for PCR reaction using 
the following conditions: 94°C for 10 minutes, 30 cycles of 94°C for 20 seconds, 
65�C for 30 seconds and 72°C for 1 minute, followed by 1 cycle of 72�C for 7 
minutes. Five |LI1 of PCR product was used for agarose/TAE gel electrophoresis. 
3.2.12 Southern Blot Analysis of Genomic DNA 
Twenty i^g of genomic DNA was digested with Hindlll for 16 hours, separated 
on 0.8% agarose/TAE gel at 45V for approximately 3 hours and transferred to a 
positively charged nylon membrane (Roche) using the VacuGeneXL Vacuum 
blotting System (Pharmacia Biotech). After UV-crosslinking, the membrane was 
prehybridized in Church buffer [7% SDS，50% formamide, 5X SSC, 2% blocking 
reagent, 50 mM sodium phosphate, pH 7,0 and 0.1% N-lauroylsarcosine] at 42�C for 
2 hours. Hybridization was carried out in Church buffer with 25 ng/ml of anti-sense 
DIG-labeled P30 DNA at 42°C for 16 hours. After two low stringency washes (2X 
SSC, 0.1% SDS) at room temperature for 15 minutes, the membrane was subjected 
to two high stringency washes (0.5X SSC, 0.1% SDS) at 68�C for 15 minutes. 
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Chemiluminescent detection was carried out with CSPD as described in the manual 
for DIG Luminescent Detection Kit (Roche). 
3.2.13 Extraction of Total RNA from Leaves or Developing Seeds 
Total RNA was extracted from leaves of transgenic plants transformed with the 
P30 constructs containing the constitutive promoters, pBI/35S-HP or pBI/Ubi-HP. 
For transgenic plants harboring seed-specific promoter constructs, pBI/Phas-HP or 
pBI/Phas.SP-HP, total RNA was extracted from developing seeds collected 20 days 
after flower (DAF). A small-scale RNA extraction protocol of Altenbach et al 
(1989) was used. 
About 0.3 g of plant tissue was ground into powder under liquid nitrogen with a 
mortar and pestle. After adding 0.3 ml of RNA extraction buffer [0.1 M LiCl, O.IM 
Tris-HCl, pH 8.0, 0.1 M EDTA and 1% SDS] and 0.3 ml of phenol, the sample was 
heated at 55°C for 15 minutes. An additional 0.6 ml of chloroform/ isoamyl alcohol 
(24:1, v/v) was mixed with the sample and the mixture was centrifuged at 10,000 
rpm for 5 minutes. The upper aqueous phase was transferred to a new tube, mixed 
with an equal volume of 4 M LiCl and kept at 4 � C for 2 hours. The mixture was 
then centrifuged at 14,000 rpm at 4 � C for 10 minutes. The pellet was washed with 
0.2 ml of 2 M LiCl and centrifiiged at 14,000 rpm at 4°C for 10 minutes. After 
centriftigation, the pellet was resuspended in 0.25 ml of diethylpyrocarbonate 
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(DEPC)-treated water and 25 jLil of 3 M DEPC-treated sodium acetate (pH 5.0) 
before mixing with 0.5 ml of cold absolute EtOH and kept at -20°C for 2 hours. 
The mixture was centrifuged again at 14,000 rpm at 4°C for 10 minutes. The pellet 
was washed twice with 70% EtOH, allowed to air-dry and finally dissolved in 20 |LI1 
of DEPC-treated water. 
3.2.14 Reverse Transcription-Polymerase Chain Reaction of Total RNA 
One jag of total RNA was treated with 1 unit of RQl RNase-free DNase I 
(Promega) in a 10 |al reaction at room temperature for 15 minutes to remove DNA 
contamination. The RNA sample was then denatured by heating at 65°C for 5 
minutes in a 20 |LI1 mixture containing 1 jug of total RNA and 0.25 |IG of Oligo (dT)i5 
Primer (Promega) before cooling on ice for 5 minutes. Reverse transcription was 
carried out in a 40 |LI1 reaction containing 1 |ig of total RNA, 0.25 [xg of Oligo dT 
primer, 400 units of Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase (RT) (Promega), IX M-MLV reaction buffer, 0.5 mM dNTPs, 10 mM 
DTT and 40 units of RNasin® Ribonuclease Inhibitor (Promega) at 4 2 � C for 1 hour. 
Another set of reaction without M-MLV RT was included as an internal control. 
Following first strand cDNA synthesis, cDNA amplification was performed in a 25 
reaction mixture containing 10 i^l of RT product, IX PGR buffer, 2 mM MgCb, 
0.2 mM dNTPs, 1 j^ M 5T30-PCR and 3'P30-PCR primers (Table 3- 1) and 1 unit of 
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Platinum Taq DNA polymerase (Gibco), using the following conditions: 94°C for 10 
minutes, 30 cycles of 94�C for 20 seconds, 65°C for 30 seconds and 72°C for 1 
minute, followed by 1 cycle of 72°C for 7 minutes. Ten jal of PGR products was 
used for agarose/TAE gel electrophoresis. 
3.2.15 Sequencing of RT-PCR Product 
PCR-aided sequencing of RT-PCR product was performed using the ABI 
Prism dRhodamine Terminator Cycle Sequencing Ready Kit (Applied Biosystems) 
to confirm the sequence fidelity of the P30 transcripts in the transgenic plants. 
RT-PCR product was purified using with the Wizard PCR Preps DNA 
Purification System (Promega). A 10 \x[ sequencing reaction containing 70 ng of 
RT-PCR product, 0.16 pmole ofP30-5'mid or P30-3，mid primer (Table 3- 1) and 4 
of Terminator Ready Reaction Mix was performed using the following conditions: 
96°C for 5 minutes, 25 cycles of 96�C for 10 seconds, 50�C for 5 seconds, 60�C for 
4 minutes. The sequencing product was then purified by EtOH precipitation and 
the pellet was resuspended in 12 \x\ of Template Suppression Reagent and applied to 
Genetic Analyzer ABI Prism 310 for analysis. 
3.2.16 Northern Blot Analysis of Total RNA 
Ten |Lig of total RNA was separated on 0.8% agarose/formaldehyde gel in IX 
formaldehyde gel running buffer [40 mM MOPS, pH 7.0, 10 mM sodium acetate, 1 
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mM EDTA, pH 8.0] and transferred to a positively charged nylon membrane (Roche) 
using the VacuGeneXL Vacuum blotting System (Pharmacia Biotech). After 
UV-crosslinking, the membrane was prehybridized in Church buffer [7% SDS, 50% 
formamide, 5X SSC, 2% blocking reagent, 50 mM sodium phosphate, pH 7.0 and 
0.1% N-lauroylsarcosine] at 50°C for 2 hours. Hybridization was carried out in 
Church buffer with 25 ng/ml of anti-sense DIG-labeled P30 DNA at 50°C for 16 
hours. After two low stringency washes (2X SSC, 0.1% SDS) at room temperature 
for 15 minutes, the membrane was subjected to two high stringency washes (0.5X 
SSC, 0.1% SDS) at 68°C for 15 minutes. Chemiluminescent detection was carried 
out with CSPD as described in the manual for DIG Luminescent Detection Kit 
(Roche). 
3.2.17 Extraction of Total Protein from Leaves or Mature Seeds 
Total protein was extracted from leaves of transgenic plants possessing the 
pBI/35S-HP or pBI/Ubi-HP construct while from mature seeds for those harboring 
the pBI/Phas-HP or pBI/Phas.SP-HP. 
Total protein was extracted by grinding 0.3 g of plant tissue in 1 ml of protein 
extraction buffer [0.25 M NaCl, 0.05 M sodium phosphate, pH 8.0] with a mortar 
and pestle. Homogenate was then centrifliged at 14,000 rpm for 10 minutes. 
Clear supernatant was recovered after repeated centrifugation to remove the lipid 
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layer and saved as total protein extract (TPE). The bicinochoninic acid (BCA) 
method, using bovine serum albumin (BSA) as standard, was used to quantify TPE. 
3.2.18 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
TPE (40-60 )ag) was mixed with an equal volume of 2X sample loading buffer 
[0.0625 M Tris-HCl，pH 6.8，2% SDS, 1% p-mer, 10% glycerol and 0.01% 
bromophenol blue], heated at 9 9 � C for 5 minutes and resolved by 17.5% SDS-PAGE 
in electrode buffer [0.025 M Tris，0.19 M glycine and 0.1% SDS, pH 8.3] at 30V for 
1 hour and lOOV for 1 hour and 30 minutes. After electrophoresis, the gel was 
stained in Coomassie blue solution [0.25% Coomassie brilliant blue R-250, 50% 
methanol and 10% glacial acetic acid] and then destained in destaining solution [10% 
glacial acetic acid and 50% methanol:. 
3.2.19 Purification of 6xHis-tagged Proteins 
Purification of His-tagged proteins was based on the use of Ni-NTA Spin Kit 
(QIAGEN) with modifications. About 0.3 g of plant tissue was ground into 
homogenate in 1.5 ml of Buffer B [8 M urea, 0.1 M NaH2P04and 0.01 M Tris/HCl, 
pH 8.0] and centrifuged at 14,000 rpm for 10 minutes. Protein extract was 
transferred to a pre-equilibrated Ni-NTA (nickel-nitrilotriacetic acid) spin 
column and centrifiiged at 2,000 rpm for 2 minutes. The spin column was 
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washed twice with Buffer C [8 M urea, 0.1 M NaHsPOgand 0.01 M Tris/HCl, pH 
6.3] followed by elution of the desired proteins with 100 jal of Buffer E [8 M 
urea, 0.1 M NaH2P04 and 0.01 M Tris/HCl, pH 4.5] through centrifiigation at 
2,000 rpm for 2 minutes. 
3.2.20 Western Blot Analysis of Total Protein 
Protein extract (100-200 ^ig) was first separated by 17.5% SDS-PAGE and 
blotted onto PVDF membrane (Bio-Rad) in the modified Dunn carbonate transfer 
buffer [10 mM NaHCCb and 3 mM NaiCOa] at 44V for 75 minutes using Mini 
Trans-Blot cell (Bio-Rad). The blot was then incubated with 6xHis Monoclonal 
Antibody (Clontech) at 1:5000 dilution and subjected to non-radioactive detection 
with chemiluminescent Starlight™ Substrate (ICN) as described in the manual of 
AuroraTM Western Blot Chemiluminescent Detection System (ICN). 
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3.2.21 In vitro Transcription and Translation 
3.2.21.1 Construction of Transcription Vector Containing Chimeric P30 Gene 
Two transcription vectors, one with a His-tag at the 5' end of the P30 coding 
sequence (pGEM/HP) and one without (pGEM/P)，were constructed. The P30 
fragment was excised from pET/E，P30F (Figure 3- 14) or pET/P30F (Figure 3- 15) 
and subcloned into pGEM-3Zf(+) vector (Promega) using Kpnl and Hindlll. The 
resulting constructs, with the T7 and SP6 RNA polymerase promoters flanking the 
target gene, were used for in vitro transcription. 
3.2.21.2 In vitro Transcription 
Sense P30 transcript was synthesized by in vitro transcription using the 
RiboMax™ Large Scale RNA Production Systems — T7 (Promega). The 
transcription vectors, pGEM/HP and pGEM/P, were first linearized with Hindlll. A 
reaction mix containing IX Transcription buffer (Promega), 7.5 mM of each rNTP, 6 
l^ g of linearized DNA template (or 2 jag of luciferase control DNA) and 4 of T7 
RNA polymerase enzyme mix (Promega) was set up for each transcription reaction 
and incubated at 3 7 � C for 3 hours. The quality and quantity of in vitro transcript 
was checked by electrophoresis on 1% agarose/formaldehyde gel. 
3.2.21.3 In vitro Translation 
Two in vitro translation systems were used, the Rabbit Reticulocyte Lysate (RL) 
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System and the Wheat Germ Extract (WG) System (both from Promega). 
Luciferase and Brome Mosaic Vims (BMV) in vitro transcripts were used in the 
positive (+ve) control reaction in the RL and WG systems, respectively. The 
translation reactions were as described in Tables 3 - 2 and 3-3. 
The translation products were resolved in 16.5% tricine SDS-PAGE and blotted 
onto PVDF membrane (Bio-Rad) in the modified Dunn carbonate transfer buffer at 
44V for 75 minutes using the Mini Trans-Blot cell (Bio-Rad). The blot was then 
subjected to non-radioactive detection with Transcend™ Chemiluminescent 
Substrate (Promega) as described in the manual of Transcend™ Non-Radioactive 
Translation Detection Systems (Promega). 
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V > 
Figure 3-14 Construction of transcription vector pGEM/HP 
The P30 fragment (with a His-tag) was excised from pET/E'P30F and 
subcloned into pGEM-3Zf(+) with the use of Kpnl and Hindlll, 
resulting in pGEM/HP. (MCS = multiple cloning site) 
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Figure 3-15 Construction of transcription vector pGEM/P 
The P30 fragment (without a His-tag) was excised from pET/DP30F 
and subcloned into pGEM-3Zf(+) with the use of Kpnl and Hindlll, 
resulting in pGEM/P. (MCS = multiple cloning site) 
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Table 3- 2 In vitro translation reaction in the RL system 
m n • +ve control „ . P30 in vitro /T . , Reagents ‘ . ‘ (Luciferase -ve control ^ transcript ^ .上、  transcript)  
“ RL 35 lul 35 |Lil 35 |LI1 
a. a. mix - Leu 0.5 |LI1 0.5 |LI1 0.5 jul  
a. a. mix - Met 0.5 i^l 0.5 pil 0.5 |al 
RNasin (40 u/^il) 1 1 i^l 
RNA 10 lag ™  
Transcend tRNA 1.5 i^l I j^ 1 |LI1 
Total volume 50 pil 5oVil SoVil 
In the RL system, in vitro translation was carried out at 30°C for 90 minutes. 
Table 3- 3 In vitro translation reaction in the WG system 
n ‘ P30 in vitro +ve control ^ , Reagents , . , /r»u7、，• • ‘ � -ve control  transcript (BWV transcript)  
WG 25 ml 25 lal “ 25 ml — 
a. a. mix - Leu 0.5 |LI1 0.5 0.5 JUL 
a. a. mix - Met 0.5 |LI1 0.5 |LI1 0.5 |al 
RNasin (40 u/nl) Ijd  
RNA lOjug -二 
KOAc (1 M) 2 3.5 i^l — 3.5 pil 一 
Transcend tRNA 1.5 i^l jj^J 1 
Total volume 50 i^l 50Vil “ 50 |LI1  
In the WG system, in vitro translation was carried out at 25°C for 2 hours. 
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3.3 Results 
3.3.1 Construction of Chimeric P30 Genes 
Four chimeric P30 genes, under the control of different regulatory sequences, 
were subcloned into the Agrobacterium binary vector pBI121 as described in Section 
3.2.5 and transferred into A. tumefaciens LBA4404 through electroporation for 
tobacco transformation. DNA sequencing was performed to verify that the 
transgene constructs were correct in sequence and frame. 
3.3.2 Tobacco Transformation, Selection and Regeneration 
The constructs pBI/35S-HP, pBI/Ubi-HP, pBI/Phas-HP, pBI/Phas.SP-HP and 
pBI121 (as vector-alone control) were transformed into tobacco genome via 
Agrobacterium-mQdiditQd^ transformation. 
Forty leaf disks wound with forceps were used for transformation. After 
cocultivation with Agrobacterium cells for 2 days, the explants were transferred to 
shoot regeneration medium containing kanamycin for calli and shoot formation. 
Regenerated shoots were transferred to root regeneration medium for rooting (Figure 
3- 16). Transgenic tobacco plants were finally transferred to soil in pots and 
allowed to grow in greenhouse. 
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Figure 3- 16 Tobacco transformation, selection and regeneration 
Agrobacterium tumefaciens LBA4404 harboring the target construct 
was used to infect tobacco leaf. Tobacco leaf explants (A) were 
cocultivated with Agrobacteria for 2 days. Under kanamycin 
selection, calli formed around the wounds on leaf explants and 
differentiated into shoots 2-4 weeks after transformation (B). 
Regenerated shoots were then transferred to root regeneration medium 
for rooting (C). 
66 
At the end, one wild type (WT) tobacco, one pBI121 transformant and three to 
four transformants for each chimeric P30 construct, as listed in Table 3 - 4 , were 
selected for further analysis. 
Table 3- 4 Transformants selected for further analysis 
Construct Transformant Number  
pBI121 'BI " l -
pBI/35S-HP S1,S2, S3 "3 — 
pBI/Ubi-HP m，U2,U4 —3 — 
pBI/Phas-HP P6，P15,P17，P19 _4 — 
pBI/Phas.SP-HP |PS 10, PS 17, PS 19，PS22 K 
3.3.3 Detection of GUS Activity 
Leaves from transformants were used in GUS assay. All leaves from 
transformants harboring the constructs showed positive results, i.e. turned deep blue 
while untransformed plants (WT) remained colorless after GUS staining and 
chlorophyll removal (Figure 3- 17), indicating that the GUS marker gene was 




Figure 3-17 GUS staining of tobacco leaves 
Fresh tobacco leaves were placed in GUS staining solution and 
incubated at 37°C for color development. Chlorophyll was 
removed by 70% ethanol treatment. Leaf from wild type 
tobacco remained colorless (left) while that from transgenic one 
stained blue (right). 
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3.3.4 Detection of P30 Gene in Transgenic Plants 
Besides the use of indirect means such as antibiotic selection and GUS assay, 
PGR and Southern blot analysis of genomic DNA were performed to confirm the 
integration of the P30 transgene into tobacco genome. 
Genomic DNA was extracted from tobacco leaf using the CTAB method. As 
shown in Figure 3- 18, uncut genomic DNA appeared as one major band with 
molecular weight over 15 kb. 
3.3.4.1 PGR of Genomic DNA 
Using genomic DNA as template, PGR in the presence of the P30 specific 
primers (P30-5' and P30-3，，Table 3 - 1 ) was performed. A positive control using 
pET/P30F as template was also carried out. PGR products were resolved in 1% 
agarose/TAE gel. As revealed in Figure 3- 19，all the P30 transformants gave an 
expected PCR product of 540 bp (same as +ve control) while WT did not, indicating 
that the P30 transgene was present in the genome of the P30 transformants. 
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Figure 3-18 Genomic DNA extracted from tobacco leaves using 
the CTAB method 
Intact genomic DNA extracted from tobacco leaf was resolved in 
0.7% agarose/TAE gel. 
Lanes 1 -3: pBI/35S-HP transformants SI, S2 and S3; 
Lanes 4 & 12: High Molecular Weight DNA Markers (Gibco); 
Lanes 5-7: pBI/Ubi-HP transformants Ul , U2 and U4; 
Lanes 8-11: pBI/Phas-HP transformants P6，P15, P17 and P19; 
Lanes 13-16: pBI/Phas.SP-HP transformants PS 10, PS 17，PS 19 
and PS22; 
Lane 17: Wild type (WT) tobacco; 
Lane 18: pBI121 transformant BI. 
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Figure 3-19 PCR analysis of genomic DNA from wild type and transgenic 
tobacco plants 
PCR using genomic DNA from wild type tobacco plant or P30 
transformants as template was performed using the P30 specific 
primers P30-5' and P30-3'. PCR using plasmid pET/P30F as primer 
was used as positive (+ve) control. The expected size of PCR 
product was 540 bp. 
Lanes 1-3: pBI/35S-HP transformants SI, S2 and S3; 
Lanes 4-6: pBI/Ubi-HP transformants U l , U 2 a n d U4; 
Lane 7: Wild type (WT) tobacco; 
Lane 8: 100 bp DNA ladder (Gibco); 
Lane 9: +ve control (pET/P30F); 
Lanes 10-13: pBI/Phas-HP transformants P6，P15, P17 and P19; 
Lanes 14-17: pBI/Phas.SP-HP transformants PSIO, PS 17, PS19 
and PS22. 
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3.3.4.2 Southern Blot Analysis 
The integration of chimeric P30 gene into tobacco genome was further 
confirmed by Southern blot analysis. Genomic DNA was cut with Hindlll, 
separated on 0.8% agarose/TAE gel and blotted on positively charged nylon 
membrane. After hybridization with anti-sense DIG-labeled P30 DNA probe, 
chemiluminescent detection was carried out with CSPD. 
As illustrated in Figure 3- 20，all the pBI/Phas-HP and pBI/Phas.SP 
transformants revealed a signal of about 3.2 kb, as in the positive control (plasmid 
pBI/Phas-HP cut with Hindlll). For transformants pBI/35S-HP and pBI/Ubi-HP, 
positive signals with expected sizes (about 3.1 kb and 3.5 kb, respectively) were 
detected (Figure 3- 21). No signal was detected in the wild type plant or pBI121 
transformant, showing that the signals were not due to non-specific binding of the 
probe. These results further confirmed the integration and presence of the 
transgenes in the genome of the P30 transformants. 
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Figure 3- 20 Southern blot analysis of genomic DNA from transformants 
P and PS 
Genomic DNA extracted from tobacco leaves was digested with 
Hindlll, separated on 0.8% agarose/TAE gel (lower panel), blotted on 
positively charged nylon membrane and hybridized with DIG-labeled 
P30 probe (upper panel). 
Lane 1: DNA molecular weight VII, DIG-labeled (Roche); 
Lane 2: +ve control 
(150 pg ofpBI/Phas-HP digested with Hindlll); 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5-8: pBI/Phas-HP transformants P6, P15, P17 and P19; 
Lanes 9-12: pBI/Phas.SP-HP transformants PSIO, PS17, PS19 
and PS22. 
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Figure 3-21 Southern blot analysis of genomic DNA from transformants 
S a n d U 
Genomic DNA extracted from tobacco leaves was digested with 
Hindlll, separated on 0.8% agarose/TAE gel (lower panel), blotted on 
positively charged nylon membrane and hybridized with DIG-labeled 
P30 probe (upper panel). 
Lane 1: DNA molecular weight VII, DIG-labeled (Roche); 
Lane 2: +ve control 
(150 pg ofpBI/35S-HP digested with Hindlll); 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5-7: pBI/35S-HP transformants SI, S2 and S3; 
Lanes 8-10: pBI/Ubi-HP transformants Ul , U2 and U4. 
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3.3.5 Detection of P30 Transcript in Transgenic Plants 
Total RNA was extracted from the leaves of transformants harboring the 
constitutive promoter constructs (pBI/35S-HP or pBI/Ubi-HP). Since the phaseolin 
promoter is seed-specific and temporarily regulated, total RNA for transformants 
harboring the pBI/Phas-HP or pBI/Phas.SP-HP construct was extracted from 
developing seeds collected 20 DAF instead. RT-PCR, sequencing of the RT-PCR 
products and northern blot analysis were performed to detect and confirm the 
presence and sequence fidelity of the P30 transcripts in these transformants. 
3.3.5.1 RT-PCR 
DNase I treatment of total RNA was first performed to eliminate any DNA 
contamination which may lead to false positive results in the second strand cDNA 
PCR. In the RT reaction, Oligo (dT)i5 Primer (Promega) was used and a set of 
reaction without M-MLV RT (lanes with -) was included as an internal control. 
Following cDNA synthesis, PCR with the P30 specific primers, 5T30-PCR and 
3'P30-PCR, was carried out. Ten )LI1 of PCR product was used for agarose/TAE gel 
electrophoresis. 
As revealed in Figures 3- 22 and 3- 23, all the pBI/Phas-HP and pBI/35S-HP 
transformants showed positive results in the RT-PCR with a band of 740 bp, as in 
+ve control (using pET/E'P30F as the template). However, like WT, no P30 
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transcript was detected in the pBI/Ubi-HP transformants. 
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Figure 3- 22 RT-PCR of total RNA from transformants P 
Total RNA was first treated with DNase I to remove DNA 
contaminant. RT reaction was first performed with oligo dT primer 
while the second strand cDNA PGR used the P30 specific primers 
5'P30-PCR and 3，P30-PCR. 
Lane 1: 100 bp DNA ladder (Gibco); 
Lane 2: +ve control 
(PGR of plasmid pET/E'P30F); 
Lanes 3: Wild type (WT) tobacco; 
Lanes 4-7: pBI/Phas-HP transformant P6, P15, P17 and P19; 
Lane 8: -ve control 
(PGR without template); 
Lanes with +: RT reaction with M-MLV RT; 
Lanes with -: RT reaction without M-MLV RT (internal control). 
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Figure 3- 23 RT-PCR of total RNA from transformants S and U 
Total RNA was first treated with DNase I to remove any DNA 
contaminant. RT reaction was first performed with oligo dT primer 
while the second strand cDNA PCR used the P30 specific primers 
5’P30-PCR and 3'P30-PCR. 
Lane 1: 100 bp DNA ladder (Gibco); 
Lane 2: +ve control 
(PCR ofplasmid pET/E'P30F); 
Lanes 3: Wild type(WT) tobacco; 
Lanes 4-6: pBI/35S-HP transformant SI, S2 and S3; 
Lanes 7-9: pBI/Ubi-HP transformant Ul，U2 and U4; 
Lane 10: -ve control 
(PCR without template); 
Lanes with +: RT reaction with M-MLV RT; 
Lanes with RT reaction without M-MLV RT (internal control). 
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3.3.5.2 Sequencing of RT-PCR Product 
The fidelity of the P30 transcript was further confirmed by DNA sequencing. 
Purified RT-PCR products from P17 and S2 were used as template for cycle 
sequencing using the P30 internal primer P30-5，mid or P30-3’mid. Sequencing 
products were applied to automatic DNA sequencer for analysis. Total agreement 
between the sequencing data and the original P30 sequence further confirmed the 
presence of the P30 transcription in transformants P and S. 
3.3.5.3 Northern Blot Analysis 
Total RNA extracted either from tobacco developing seeds or leaves was 
resolved in 0.8% agarose/formaldehyde gel, blotted onto positively charged nylon 
membrane and hybridized with anti-sense DIG-labeled P30 probe. The P30 
transcript HP (0.82 kb) synthesized via in vitro transcription (Section 3.2.21.2) was 
served as a positive control. 
As revealed in Figures 3- 24 and 3- 25，all the pBI/Phas.SP-HP (PSIO, PS 17， 
PS19 and PS22), pBI/35S-HP (SI, S2 and S3) and two of the pBI/Phas-HP (P15 and 
PI9) transformants showed positive signals in the northern blot analysis. No signal 
was detected in the pBI/Ubi-HP transformants, in agreement with the RT-PCR 
results shown in Section 3.3.5.1. Transformants PS 19, PS22, SI and S3 appeared to 
have relatively higher levels of production of the P30 transcripts in comparison to 
79 
other P30 transformants. 
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Figure 3- 24 Northern blot analysis of total RNA from transformants P and PS 
Total RNA extracted from tobacco developing seeds was separated on 
0.8% agarose/formaldehyde gel (lower panel), blotted onto positively 
charged nylon membrane and hybridized with the DIG-labeled P30 
probe (upper panel). 
Lanes 1 & 14: RNA Markers, 0.28-6.58 kb (Promega); 
Lanes 2 & 3: +ve control 
(150 & 100 ng of w vitro P30 transcript HP with a size 
about 820 bases); 
Lane 4: Wild type (WT) tobacco; 
Lane 5: pBI 121 transformant BI; 
Lanes 6-9: pBI/Phas.SP-HP transformants PS 10, PS 17，PS 19 
and PS22; 
Lanes 10-13: pBI/Phas-HP transformants P6, P15, P17 and P19. 
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Figure 3- 25 Northern blot analysis of total RNA from transformants S and U 
Total RNA extracted from tobacco leaves was separated on 0.8% 
agarose/formaldehyde gel (lower panel), blotted onto positively 
charged nylon membrane and hybridized with the DIG-labeled P30 
probe (upper panel). 
Lane 1: +ve control 
(100 ng of in vitro P30 transcript HP with a size about 
820 bases); 
Lanes 2 & 4: Blank; 
Lane 3: RNA Markers, 0.28-6.58 kb (Promega); 
Lane 5: Wild type (WT) tobacco; 
Lane 6: pBI 121 transformant BI; 
Lanes 7-9: pBI/35S-HP transformants SI, S2 and S3; 
Lanes 10-12: pBI/Ubi-HP transformants U1, U2 and U4. 
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3.3.6 Detection of P30 Protein in Transgenic Plants 
Total protein was extracted with phosphate extraction buffer from mature seeds 
of pBI/Phas-HP and pBI/Phas.SP transformants or from leaves of pBI/35S-HP 
transformants. Since recombinant P30 proteins were His-tagged, the Ni-NTA spin 
kit was also used to purify and concentrate any possible His-tagged proteins in the 
transgenic samples. The protein profiles were revealed by 17.5% SDS-PAGE after 
staining with Coomassie blue solution (Figures 3- 26 to 3- 29). Recombinant P30 
proteins should have molecular weights around 26 kDa to 29 kDa. However, no 
obvious difference could be observed between the protein profiles of wild type, 
pBI121 transformants and the P30 transformants. As the amounts of recombinant 
P30 proteins might not be sufficiently abundant to detect by Coomassie blue staining, 
more sensitive and precise western blot analysis was performed. 
3.3.6.1 Western Blot Analysis of Total Protein and Ni-NTA Purified Proteins 
Protein extract or purified His-tagged protein (100-200 |ig) was separated by 
17.5% SDS-PAGE, blotted onto PVDF membrane and incubated with 6xHis 
Monoclonal Antibody (Clontech) at 1:5000 dilution. A 6xHis ladder (QIAGEN) 
was served as both molecular size marker and positive control. After 
chemiluminescent detection, the positive control gave a strong signal but no signal 
was found in the P30 transformants (Figures 3- 30 to 3- 33). 
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Figure 3- 26 SDS-PAGE of total protein from tobacco leaves 
Total protein (60 )ag) was extracted from tobacco leaves, resolved in 
17.5% SDS-PAGE and stained with Coomassie blue. 
Lane 1: SIGMAMARKER Low Molecular Weight Range 
(Sigma); 
Lanes 2 & 8: Blank; 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5-7: pBI/35S-HP transformants SI, S2 and S3. 
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Figure 3- 27 SDS-PAGE of total protein from tobacco mature seeds 
Total protein (40 |j,g) was extracted from tobacco mature seeds, 
resolved in 17.5% SDS-PAGE and stained with Coomassie blue. 
Lane 1: SIGMAMARKER Low Molecular Weight Range 
(Sigma); 
Lane 2: Blank; 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5 & 6: pBI/Phas-HP transformants P15 and P19; 
Lanes 7 & 8: pBI/Phas.SP-HP transformants PS 19 and PS22. 
85 
kDa 1 2 3 4 5 6 
i ：哪flHW 
i " Expected size 
25 - m of P30 protein 
Figure 3- 28 SDS-PAGE of Ni-NTA purified proteins from tobacco leaves 
Ni-NTA purified proteins were obtained from tobacco leaf extract 
after interaction with Ni-NTA spin column, resolved in 17.5% 
SDS-PAGE and stained with Coomassie blue. 
Lane 1: BenchMark Prestained Protein Ladder (Gibco); 
Lane 2: Wild type (WT) tobacco; 
Lane 3: pBI 121 transformant BI; 
Lanes 4-6: pBI/35S-HP transformants SI, S2 and S3. 
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Figure 3- 29 SDS-PAGE of Ni-NTA purified proteins from tobacco seeds 
Ni-NTA purified proteins were obtained from tobacco mature seeds 
after interaction with Ni-NTA spin column, resolved in 17.5% 
SDS-PAGE and stained with Coomassie blue. 
Lane 1: BenchMark Protein Ladder (Gibco); 
Lane 2: Wild type (WT) tobacco; 
Lane 3: pBI 121 transformant BI; 
Lanes 4 & 5: pBI/Phas-HP transformants P15 and P19; 
Lanes 6 & 7: pBI/Phas.SP-HP transformants PS 19 and PS22. 
87 
kDa 1 2 3 4 5 6 7 8 
100 — 
iiiimilimiBitiii * ’ J 类 
50 — N '禱 . . ’ 
30 — f P Expected size 
^ of P30 protein 
(-26 kDa) 
15 —I • ,;:’, ‘>: i 
Figure 3- 30 Western blot analysis of total protein from tobacco leaves 
Total protein (150 fag) was extracted from tobacco leaves, resolved in 
17.5% SDS-PAGE and blotted on PVDF membrane. Western blot 
analysis using 6xHis Monoclonal Antibody (Clontech) was carried 
out. 
Lane 1: 6xHis ladder (QIAGEN); 
Lanes 2 & 8: Blank; 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5-7: pBI/35S-HP transformants SI, S2 and S3. 
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Figure 3- 31 Western blot analysis of total protein from tobacco seeds 
Total protein (200 ]Lig) was extracted from tobacco mature seeds, 
resolved in 17.5% SDS-PAGE and blotted on PVDF membrane. 
Western blot analysis using 6xHis Monoclonal Antibody (Clontech) 
was carried out. 
Lane 1: 6xHis ladder (QIAGEN); 
Lane 2: Blank; 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5 & 6: pBI/Phas-HP transformants P15 and P19; 
Lanes 7 & 8: pBI/Phas.SP-HP transformants PS19 and PS22. 
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Figure 3- 32 Western blot analysis of Ni-NTA purified proteins from 
tobacco leaves 
Ni-NTA purified proteins (200 jiig) were obtained from tobacco leaves 
after reaction with Ni-NTA spin column, resolved in 17.5% 
SDS-PAGE and blotted on PVDF membrane. Western blot analysis 
using 6xHis Monoclonal Antibody (Clontech) was carried out. 
Lane 1: 6xHis ladder (QIAGEN); 
Lanes 2 & 8: Blank; 
Lane 3: Wild type (WT) tobacco; 
Lane 4: pBI 121 transformant BI; 
Lanes 5-7: pBI/35S-HP transformants SI, S2 and S3. 
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Figure 3- 33 Western blot analysis of Ni-NTA purified proteins from 
tobacco seeds 
Ni-NTA purified proteins (200 |ag) were obtained from tobacco 
mature seeds after reaction with Ni-NTA spin column, resolved in 
17.5% SDS-PAGE and blotted on PVDF membrane. Western blot 
analysis using 6xHis Monoclonal Antibody (Clontech) was carried 
out. 
Lane 1: 6xHis ladder (QIAGEN); 
Lane 2: Wild type (WT) tobacco; 
Lane 3: pBI 121 transformant BI; 
Lanes 4 & 5: pBI/Phas-HP transformants P15 andP19; 
Lanes 6 & 7: pBI/Phas.SP-HP transformants PS 19 and PS22. 
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3.3.7 In vitro Transcription and Translation 
In vitro transcription and translation were performed to further investigate the 
translatability of chimeric P30 transcripts. 
Two transcription vectors, one with a His-tag at the 5' end of the P30 coding 
sequence (pGEM/HP) and one without (pGEM/P), were constructed as described in 
Section 3.2.21.1. 
3.3.7.1 In vitro Transcription 
Using the RiboMax™ Large Scale RNA Production Systems - T7, sense P30 in 
vitro transcripts HP and P with sizes of about 0.82 kb and 0.8 kb were generated 
from Hindlll-linearized pGEM/HP and pGEM/P, respectively. Luciferase control 
DNA was used as +ve control and its in vitro transcript was 1.8 kb in length (Figure 
3- 34). 
3.3.7.2 In vitro Translation 
In vitro translation was conducted in 2 systems: an animal cell-free translation 
system, rabbit reticulocyte lysate (RL) and a plant system, wheat germ extract (WG). 
During translation, biotinylated lysine residues (as a precharged e-labeled 
biotinylated lysine-tRNA complex named Transcend™ tRNA) were incorporated 
into nascent proteins. The translation products were resolved in 16.5% tricine 
SDS-PAGE and blotted on PVDF membrane. Non-radioactive detection with 
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Streptavidin-Horseradish Peroxidase was carried out to visualize the biotinylated 
proteins. 
The expected sizes of in vitro translation products of the P30 in vitro transcripts 
HP and P would be 25.7 kDa and 24.1 kDa, respectively. As shown in Figure 3- 35, 
in the RL system, luciferase in vitro transcript (+ve control) gave an expected band 
of 61 kDa. Using the in vitro produced P30 transcripts, in vitro translation products 
of expected sizes could also be detected. However, in the WG system, only the 
expected translation products of BMV with a size of 35 kDa was detected. No 
signal was found for the P30 in vitro transcripts (Figure 3-36). The results suggest 
that the translation of the P30 transcript may not be efficient in the plant system. 
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Figure 3- 34 Transcripts synthesized in in vitro transcription 
In vitro transcripts were resloved in 1% agarose/formaldehyde 
gel. 
Lane 1: RNA Markers, 0.28-6.58 kb (Promega); 
Lane 2: In vitro transcript HP (from pGEM/HP); 
Lane 3: In vitro transcript P (from pGEM/P); 
Lane 4: Luciferase in vitro transcript (+ve control). 
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Figure 3- 35 Tricine SDS-PAGE (A) and non-radioactive detection (B) of 
in vitro translation products from the RL system 
In vitro translation products from the RL system were resolved in 
16.5% tricine SDS-PAGE and stained with Coomassie blue (Panel A) 
or blotted onto PVDF membrane for non-radioactive detection with 
Streptavidin-Horseradish Peroxidase to visualize the biotinylated 
proteins (Panel B). 
Lane 1: Rainbow^^ coloured protein molecular weight markers, 
High molecular weight range (Amersham Pharmacia); 
Lane 2: +ve control (luciferase in vitro translation product); 
Lanes 3 & 5: in vitro translation product HP (from pGEM/HP); 
Lanes 4 & 6: in vitro translation product P (from pGEM/P); 
Lane 7: -ve control (no transcript added in translation). 
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Figure 3- 36 Tricine SDS-PAGE (A) and non-radioactive detection (B) of 
in vitro translation products from the WG system 
In vitro translation products from the WG system were resolved in 
16.5% tricine SDS-PAGE and stained with Coomassie blue (Panel A) 
or blotted onto PVDF membrane for non-radioactive detection with 
Streptavidin-Horseradish Peroxidase to visualize the biotinylated 
proteins (Panel B). 
Lane 1: Rainbow^^ coloured protein molecular weight markers, 
High molecular weight range (Amersham Pharmacia); 
Lane 2: +ve control (BMV in vitro translation product); 
Lanes 3 & 5: in vitro translation product HP (from pGEM/HP); 
Lanes 4 & 6: in vitro translation product P (from pGEM/P); 
Lane 7: -ve control (no transcript added in translation). 
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Chapter 4 Discussion 
4.1 General Conclusion 
P30 is a major surface antigen from a widespread intracellular parasite T. gondii 
that is responsible for toxoplasmosis. Because of its importance in studying the 
immune and pathogenic mechanisms of the parasite and in possible development of 
subunit vaccine, production of large amounts of high quality P30 by recombinant 
DNA technology becomes valuable. Successful expression of the P30 protein in 
bacteria, yeast, insect cells and animal cells have been reported (Section 2.3). 
However, so far, there has been no publication on P30 expression in plants. 
With the advances in plant biotechnology using plants as bioreactors to produce 
recombinant proteins such as antibodies and vaccines in bulk amounts at relatively 
low costs generates much commercial interest. Plant protein expression system 
shows several important advantages over other heterologous expression systems 
since plants can be grown easily and inexpensively in large scale. Moreover, 
scale-up, harvesting, transporting, storage and processing of plants can be simple and 
efficient with the available agronomic infrastructures (Fischer et al., 1999). The 
presence of nearly all post-translational modifications essential for optimal biological 
activity of proteins is also an advantage of plants in expressing eukaryotic genes. 
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Furthermore, safe recombinant proteins can be obtained, as contamination of 
expressed proteins with human or animal pathogens or other infectious diseases will 
not occur in plants (Fischer and Emans, 2000). Despite all the above advantages, 
introducing a foreign gene into a plant host does not always result in high-level 
expression or even expression of the introduced gene at all. Effective use of plants 
as bioreactors thus depends on the ability to obtain high protein accumulation levels 
that are stable during the life cycle of a transgenic plant and in subsequent 
generations. 
This work reports the first use of tobacco plants to express P30 of T. gondii. In 
the study, chimeric P30 genes under the control of the CaMV 35S, Ubi or phaseolin 
(with or without SP) promoter were constructed and introduced into tobacco via 
Agrobacterium-mQ6\?XQd transformation. Regenerated plants were first selected 
based on their kanamycin resistance (NPTII gene expression) and then screened with 
GUS assay (GUS gene expression). In genomic DNA PCR (Figure 3- 19) and 
Southern blot analysis (Figures 3- 20 and 3- 21), all the P30 transformants showed 
positive results with correct fragment size confirming the integration of the P30 
transgene into tobacco genome without any sequence rearrangement. The 
presences of the P30 transcripts in some of the P30 transformants including the 
pBI/Phas.SP-HP transformants PSIO, PS17，PS19 and PS22; pBI/35S-HP 
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transformants SI, S2 and S3; and pBI/Phas-HP transformants P15 and PI9，were 
revealed by RT-PCR (Figures 3- 22 and 3- 23) and northern blot analysis (Figures 3-
24 and 3- 25). The fidelity of the P30 transcripts was further confirmed by 
sequencing of the RT-PCR products. Despite the presences of the P30 transgene 
constructs and transcripts, no recombinant P30 protein could be detected with 
SDS-PAGE (Figures 3- 26 to 3- 29) or western blot analysis (Figures 3- 30 to 3- 33) 
in any P30 transformant. Thus there might be no or very low level of P30 
expression (not detectable by the methods employed) in the P30 transformants. 
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4.2 Further Speculations and Investigations 
4.2.1 Other Protein Detection Procedures 
Possible degradation of recombinant P30 protein during extraction might be 
reduced by adding protease inhibitors to the protein extraction buffer and carrying 
out the extraction procedure on ice. 
As the recombinant P30 protein may be very low in amount, isoelectric 
precipitation, freeze-drying or immunoprecipitation with anti-P30 antiserum could be 
used to concentrate the crude protein extract before further detection. 
4.2.2 In vitro Transcription and Translation 
Since the problem encountered was at the protein level, in vitro transcription 
and translation was conducted to investigate the translatability of the P30 transcripts. 
In vitro translation products of expected sizes, 25.7 kDa and 24.1 kDa for the P30 
proteins with or without a His-tag, respectively, could be detected in the RL system 
(Figure 3- 35) but not in the WG system (Figure 3- 36). These results indicated that 
the chimeric P30 genes could be transcribed and translated. Perhaps it is not 
surprising that the P30 gene can be expressed in the RL system as the in vitro 
reactions were optimized by the manufacturer with the addition of tRNA 
complement from calf thymus, the use of up to 2 i^g of in vitro P30 transcript and the 
absence of protein degradation system. Moreover, the P30 gene had already been 
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showed to express successfully in animal cells (Kim et al., 1994). However, the 
failure of the WG system in producing the P30 protein requires further studies. 
4.2.3 Gene Silencing at Transcription and/or Post-transcription 
Levels 
For the P30 transformants U l , U2，and U4 harboring the pBI/Ubi-HP, transgene 
inactivation might have occurred at the transcription and/or post-transcription levels 
as no P30 transcript could be detected. Since the P30 transgenes were inserted into 
plant genome in a more or less random fashion, they might integrate into 
hypermethylated chromosomal regions. This so-called position effect would result 
in spreading of the methylation pattern to transgenes and inactivating transgene 
transcription (Prols and Meyer, 1992). Transcriptional gene silencing (TGS), as 
characterized by reduced transcription of transgene that shares sequence homology in 
the promoter region in the nucleus and associated with de novo methylation of the 
promoter region of the affected locus (Vaucheret et al., 1998), might be another 
possibility. 
On the other hand, transcription might have occurred but the transcripts were 
degraded and could not accumulate to a detectable level. In this case, 
post-transcriptional gene silencing (PTGS), which reduced stable transcript 
accumulation in the cytoplasm after transcription of the transgene via 
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sequence-specific RNA degradation and associated with coding sequence 
methylation (Vaucheret et aL, 1998), might occur. PTGS could result from 
trans-intQYSiCtion between multiple copies of transgenes, between transgenes 
introduced by successive transformation and between transgenes and homologous 
host genes (Meyer and Saedler, 1996). 
4.2.4 Gene Silencing at Translation and/or Post-translation Levels 
Since the P30 gene could be transcribed and the steady-state mRNA level did 
not seem to be affected, position effect, TGS or PTGS might not be applicable to 
transformants S, P and PS. Poor P30 expression in these transgenic plants might 
occur at the translation and/or post-translation levels. Translation of the 
recombinant P30 transcripts might not be efficient or the resulting proteins were 
unstable and degraded after translation. Some possible factors contributing to the 
poor P30 expression in this respect are discussed below. 
(A) AUG Context Sequence 
The consensus nucleotide sequence surrounding translation initiation codon 
(AUG) is an important determinant of gene expression level. The effect of the 
consensus sequence of translation initiation codon in plants had been investigated. 
Expression cassette containing the GUS coding sequence fused with a plant AUG 
context sequence (AACAAUGG) under the control of CaMV 35S promoter was 
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delivered in tobacco mesophyll protoplasts. A three-fold increase in GUS activity 
was reported as compared to the control (Guerineau et al, 1992). In the present 
study, this AUG context sequence was not included which might lead to inefficient 
translation initiation of the P30 sequence. 
(B) Codon Usage 
In addition to AUG context sequence, the difference in codon usage in tobacco 
and T. gondii might also be a factor contributing to the poor P30 expression. With 
the exception of Met and Trp, all amino acids are encoded by two to six synonymous 
codons. Nonrandom usage of synonymous codons is a widespread phenomenon in 
the majority of species studied to date. This codon bias is suggested to be related to 
the abundance of corresponding isoaccepting tRNA so as to ensure translation 
accuracy and efficiency (Ikemura, 1982). The choice of codons has been thought to 
affect the translation rate. A probable mechanism in explaining the negative 
influence of the rare codons on translation is that a ribosome may stall when 
encountering a rare codon as it may take longer time for a rare tRNA to enter the 
A-site of the ribosome (Yanofsky, 1981). 
One example on enhanced gene expression in plants by changing the rare 
codons to more typical ones is the green fluorescent protein (GFP) from Aequorea 
victoria. By increasing the G+C content of the gene and removing the cryptic 
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introns and potential polyadenylation sites, one full-size GFP was found in 
transgenic tobacco while only small and truncated fragments of wild-type GFP were 
observed in transgenic plants harboring the unmodified gene (Rouwendal et al., 
1997). 
Based on the assumption that the more frequently used codons have a greater 
proportion of tRNAs and hence better translation, these frequently used codons are 
thus more preferred in that organism. As the P30 gene is originated from protozoan, 
its codon usage is quite different from that of the plants (Table 4- 1). The 
frequently used codons AUC, GUC, UCG, AGC, CCC，ACA，ACG, GCC, GCG, 
GAC, UGC (shown in red and shaded in Table 4- 1) in the P30 gene are quite rarely 
used in tobacco. These differences in codon usage might result in inefficient 
translation of the P30 sequence in tobacco. 
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Table 4-1 Comparison of codon usage frequency in N, tabacum, T. gondii 
and the P30 gene 
Amino ^ . . Frequency (per 1000) Frequency (per 1000) Frequency (per 1000) 
acid in N. tabacum in T. gondii in P30  
“ UUU 24.1 ^ 12.4 
e UUC 17.8 25.4 12.4 
UUA — 11.9 4.3 - 4.1 
UUG 21.9 15.7 16.5 “ 
T CUU 242 14?7 12A 
Leu  
c u c u ^ ^ ^  
CUA~ 8.9 — 2.3 4.1 
CUG 一 10.5 22.2 “ 8.3 
AUU 28.0 172 16.5 
lie ；.AlJC' ‘ '一 14:0"'^  '' “ - ‘ ‘ "' •2i':T … M 广 ’ 
A l ^ 12^ ^ 0 
AUG" 24.2 — 21.3 16.5 
GUU 27.6 17.4 8.3 
fetJC “ • ‘‘ ‘ ‘ ““ 1 r 5' ” ，- * 2 7 ' 4 * ‘ ^ .一 卜 广 
GUA l U O  
GUG — 16.9 23.7 — 20.7 
UCU 一 20.3 13.4 “ 8.3 
u c c " 10.5 — 12.6 12.4 
c UCA 一 17.2 7.8 “ 16.5 
^cr pYiPJFTir' " " " ‘ " KW^W.-V'••‘ ~~• ‘ 
AGU 12.7 9.7 
r w 鮮 T 贿 
CCU ^  
Pro ‘ --14.0"：^ 
CCA ^ UA ^  
CCG 4.7 15.2 — 4.1 
ACU 一 21.5 13.3 28.9 
Th ACC 一 10.0 15.7 8.3 
^ ACA 17.0 14.4 45.5 - ji 
GCU ^ ^  
Ala ； GCC 12,9 :’：..:.，麗：二 l lg . . : :纖 : : : . : : .� . :� 
GCA ^ ^  
K Q O k 5 X -二工； 
UAU \7J ^ 0 
yr UAC— 13.6 15.6 12.4 
UAA — 1.2 1.1 — 0 
*** UAG — 0.5 0.5 ~ 0 
UGA — 1.1 0.8 — 4.1 
CAU — 13.0 7.1 24.8 
IS CAC 8.9 12.8 8.3 
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Amino 介. . Frequency (per 1000) Frequency (per 1000) Frequency (per 1000) 
acid in N. tabacum in T. gondii in P30 gene 
~ CAA — 21.2 12^ 12A  
“ CAG — 15.4 24.4 16.5 
‘ AAU 122 
A G | |  
AAC m ^  
~ T AAA — 30.6 20.3 — 37.2 • 
ys AAG 33.7 — 34.2 41.3 一 
GAU 一 35.6 18.9 “ 20.7 
, ？,、【 IS^'Z . » J^aP ^ �-, •• � • 从4.. ’ .. '%M 
GAA ^ ^ ^  
u GAG 28.6 — 36.9 28.9 “ 
UGU 10.2 7.0 16.5 
Trp UGG n ^ ^ ^  
CGU 7.7 — 9.2 0 “ 
CGC 4.0 — 15.0 0 -
CGA 一 5.2 9.1 “ 0 
rg CGG 一 3.7 7.6 “ 0 
AGA~ 15.1 “ 10.1 4.1 
AGG — 12.4 7.5 — 8.3 
GGU — 24.2 20.5 — 33.1 
GGC 一 11.9 27.4 “ 4.1 
y GGA 一 24.0 20.3 “ 20.7 
GGG 10.5 12.4 20.7 
The frequencies of codon usage are computed from gene sequences available in the 
GeneBank Release (October 05, 2000). The frequency per 1000 of codons used in 
each organism or gene was calculated by summing up the numbers of each codon 
used. Data were based on a total number of 281,365 codons for N. tabacum, 60,724 
codons for T. gondii and 244 codons for the P30 gene with a His-tag. Possible 
differences of codon usage are shaded and in red. *** represents stop codon, 
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(C) N-end Rule 
In general, the N-terminal sequence of a protein may influence its stability. 
After the removal of the N-terminal Met by aminopeptidase, the second amino acid 
becomes the leading one. By the N-end rule, certain amino acids such as Met, Ala, 
Gly, Ser, Thr, or Val at the N-terminal can confer stabilizing effect to the protein in 
cytosol. However, when amino acid such as Lys, Arg, His, Phe, Tyr, Tip, He, Leu, 
Asp, Glu, Gin, or Asn is present instead, the proteins will be degraded rapidly by the 
ubiquitin-dependent proteolytic pathway in the cytoplasm and nucleus (Varshavsky, 
1997). In this study, the P30 proteins initiated with Met, and with His (from the 
His-tag) as the second amino acid, which might render protein instability. 
(D) Phaseolin Sorting Signal 
Phaseolin is the major storage protein of French bean. According to Frigerio 
et al (1998), removal of the last four C-terminal amino acids, AFVY (Ala, Phe, Val 
and Tyr) allows correct trimer formation but causes phaseolin to be secreted into 
apoplast instead of accumulated in the protein storage vacuoles. The fact that the 
AFVY tetrapeptide alone is sufficient for sorting protein to the vacuole was further 
demonstrated by fusing this tetrapeptide to a secreted version of GFP under the 
control of CaMV 35S promoter. After transfecting this fusion construct into 
tobacco protoplasts, it was found that the reporter GFP was redirected to and 
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accumulated in vacuoles (Frigerio et al., 2001). 
In this research, the transformants with the pBI/Phas.SP-HP were expected to 
have their recombinant P30 protein targeted into seed protein bodies since phaseolin 
SP was present. However, no such AFVY tetrapeptide was included or appeared at 
the C-terminal of P30. So recombinant P30 protein, at least for the constructs with 
signal peptide, if produced, would enter ER but not be further sorted to protein 
bodies. It might be secreted to apoplast and/or being degraded instead. 
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Chapter 5 Future Perspectives 
In this study, the expression of the P30 chimeric genes in tobacco seemed to be 
blocked at translation and/or post-translation levels. Future studies thus will focus 
on improving the P30 translation efficiency and protein stability. Two studies have 
been initiated in this connection: (1) codon modification of the P30 gene to 
investigate the effect of P30 codon usage on gene expression in plants and at the 
same time to optimize its expression and (2) the fusion of the P30 gene with a seed 
protein gene which had shown high and stable expression in transgenic plants, with 
an aim to stabilize the P30 protein in plants. 
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5.1 Codon Modification of the P30 Gene 
Since codon usage in the P30 gene is quite different from that of plants, it was 
suspected that this might be a cause of the poor P30 expression. To investigate the 
effect of P30 codon usage on gene expression in plants, the codons of the P30 gene 
was modified based on the preferred codons used in two seed storage proteins. 
Codon usage of lysine-rich protein (LRP) from winged bean (Figure 5- 1; Table 5- 1) 
and methionine-rich 2S albumin (PN2S) from Paradise nut (Figure 5- 2; Table 5- 2) 
were chosen as the bases for modification because high expression and stable 
accumulation (3-10% and 3-15% of total extractable seed proteins for LRP and 
PN2S, respectively) in transgenic Arabidopsis was observed in previous studies 











Figure 5- 1 Nucleotide sequence of the LRP cDNA from winged bean 
The full length of LRP cDNA is 477 bp. The start (ATG) and stop 









Figure 5- 2 Nucleotide sequence of the PN2S cDNA from Paradise nut 
The full length of PN2S cDNA is 435 bp. The start (ATG) and stop 
(TGA) codons are shaded. 
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Table 5- 1 Summary of codon usage in LRP 
[Codon Count % Codon Count % Codon Count % Codon Count % 
inr-Phe 5 3." 14 ITCT-Ser 3 1.88 TAT-Tyr 1 0.6~TGT-Cy3 0 0.00 
rrC-Phe 2 1.25 TCC-Ser 2 1.25 TAC-Tvr 6 S.VTpGC-Cvs 0 0.00 
TTA-Leu 0 0.00 TCA-Ser 2 1.25 TAA-*** 0 0.00 TGA-*** 1 0.62 
丁CG-Sei: 0 0.00 TAG-^*^ 0 0.00 TGG-Trp 0 0.00 
CTT-Leu 2 1.25 CCT-Pro 4 2.51 CAT-His I 0.62 CGT-Acg 0 0.00 
CTC-Leu 3 1.88 C C C - P e o 1 0.62 ：AC-His 1 0.62 CGC-Arg 0 0.00 
CTA-Leu 0 0.00 CCA-Pro 3 1.88 CAA-Qln 1 0.62 CGA-Arg 0 0.00 
CTG-Leu 0 0.00 CCG-Pro 0 0.00 CAG-Gln 0 0.00 CGG-Arg 0 0.00 IATT-Ile 4 2.51 iCT-Thr 2 1.55 iUT-Asn 4 2.51 AGT-Ser 2 1.25 
ATC-Ile 4 2.51 iCC-Thr 3 1.88 ！UC-Asn 1 0.62 AGC-Ser 3 1.88 
ATA-He 2 1.25 kCk-Thz 3 1.88 ！UU-Lys 8 5.03 AGA-Arg 0 0.00 
ATG-Het 1 0.62 [ACG-Tlir 0 0.00 [AAG-Lys 9 5.66 AGG-Arg 0 0.00 
IGTT-Val 10 6.28 IGCT-Ala 12 7.54 IGAT-Asp 8 5.03 GGT-Gly 6 3.77" 
GTC-Val 0 0.00 GCC-Ala 2 1.25 GAC-Asp 1 0.62 GGC-Gly 2 1.25 
GTA-Val 0 O.QQ GCA-Ala 1 0.62 GAA-Glu 6 3.77 丄y ^ 
IGTG-Val 4 2.5T" GCG-Ala 0 0.00 GAG-Glu 10 6.28 |GGG-Gly 2 1.25 
The full length of LRP cDNA is 477 bp with 159 codons and 43.6% G+C content. 
Codons in preference for each amino acid are boxed. 
Table 5- 2 Summary of codon usage in PN2S 
Codon Count h Codon Count % Codon Count H Codon Count % 
TTT-Phe 0 0.00 TCT-Ser I 0.68 TAT-Tyr 0 0.00 ~ TGT-Cys 0 0.00 
TTC-Phe 2 1.37 TCC-Ser 2 1.37 TAC-Tvr 2 1.37 i F H ^ ^ s 8 5.51_ 
TTA-Leu 1 0.68 TCA-Ser 0 0.00 TAA-*** 0 0.00 TGA-*** 1 0.68 
TTG-Leu 0 0.00 TCG-Ser 0 0.00 TAG-*** 0 0.00 TGG-Trp 0 0.00 
CTT-Leu I 0.68 CCT-Pro I 0.68 CAT-His 0 0.00 CGT-Arg 0 0.00 
CTC-Leu 6 4. iT" CCC-Pro 4 2.75 ~ - H i 3 4 2.75 CGC-Arcf 2 1.37 
CTA-Leu 0 0.00 CCA-Pro 0 0.00 CAA-Gln 3 2.06 CGA-Arg 1 0.68 
CTG-Leu 2 1.37 CCG-Pro 2 1.37 CAG-Gln 16 i.TT' CGG-Arg 4 2.75 
ATT-Ile I 0.68 ACT-Thr 0 0.00 AAT-Asn 1 0.68 AGT-Ser I 0.68 
ATC-Ile 1 0.68 ACC-Thr 5 3.4T" AAC-Asn 2 1.37 AGC-Ser 5 3.47" 
ATA-He 1 0.68 ACA-Thr 1 0.68 AAA-Lys 0 0.00 AGA-Arg 4 2.75 
ATG-Het 18 12.41 ACG-Thr 0 0.00 AAG-Lys 3 2.06 AGG-Arg 5 3.44 
GTT-Val 2 1.37 GCT-Ala 0 0.00 GAT-Asp I 0.68 GGT-Gly I 0.68 
1 0.68 GCC-Ala 6 4 . 7 ^ GAC-Asp 1 0.68 GGC-Gly 3 2.06 
GTA-Val 0 0.00 GCA-Ala 1 0.68 GAA-Glu 1 0.68 GGA-Gly 2 1.37 
GTC-Val 3 2.06 GCG-Ala 1 0.68 Ig ll.l!l5 GGG-Gly 1 0.68 
The full length of PN2S cDNA is 435 bp with 145 codons and 60% G+C content. 
Codons in preference for each amino acid are boxed. 
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By comparing the frequency of codon usage, priority ranking of synonymous 
codons for each amino acid was performed (Table 5 -3 ) . It was assumed that the 
most frequently used codons for each amino acid are the most preferred ones. 
Codon usage tables for the P30 gene before (OP30) and after (MP30) codon 
modifications were showed in Tables 5- 4 and 5-5，respectively. Codons in the P30 
gene were optimized to the corresponding preferred ones (summarized in Table 5-3) 
with the ist priority codons as top choices followed by the priority ones. The 
modified P30 (MP30) gene was synthesized by Integrated DNA Technologies, Inc. 
(Coralville, lA，USA), as illustrated in Figure 5- 3. The length of the MP30 gene 
(from start to stop codon) is 696 bp. After modification, 96 nucleotides were 
changed, representing 9.7% modification. A plant AUG context sequence 
(AACAATGG) was introduced at the 5' end of the gene to enhance translation 
initiation. According to the N-end rule, Ala was added as the amino acid to 
stabilize the protein in cytosol. Two chimeric MP30 genes under the control of the 
CaMV 35S or phaseolin promoter were constructed and transformed into 
Arabidopsis via Agrobacterium-mQ&\2iiQd transformation. Expression studies will 
be carried out in the near future. 
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Table 5- 3 Summary of codon preference prioritized based 
on the LRP and PN2S sequences 
. . . , Triplet Ammo acid ~~r—:： ^nd K .. ^ ^ ^  1 priority 2 priority 3 priority 
Phe TTT / TTC -
Leu CTC TTG 一 CTT/CTG 
lie ATT/ATC ATA 一 - — 
Met ATG - — - — 
Val GTT — GTG 一 -
Ser AGC — AGT/TCT/TCC TCA — 
Pro CCT / CCC — CCA CCG — 
Thr ACC ACA ACT 一 
Ala GCT GCC 一 -
Tyr TAG ~ - — 
H ^ CAC - - -
Gin CAA — CAG - 一 
Asn AAT/AAC - -
Lys ~ A A A / AAG — - - — 
^ GAT GAC — -
^ GAG GAA -
Cys — TGC 一 - -
T r^ TGG - 一 -
Arg CGG / AGA /AGG CGC -
Gly GGC / GGA GGT GGG 
*** TGA - -
Codons of pt priority are the ones that appear to be most frequently used in LRP and 
PN2S, and the as second frequently and so on. *** represents stop codon. 
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Table 5- 4 Summary of codon usage in the original P30 (OP30) 
Codon Count % Codon Count h Codon Count H Codon Count h 
TTT-Phe 3 1.29 TCT-Ser 2 0.86 TAT-Tyr 0 0.00 TGT-Cys 4 1.72 
TTC-Phe 3 1.29 TCC-Ser 3 1.29 TAC-Tyr 3 1.29 TGC-Cys 7 3.01 
TTA-Leu 1 0.43 TCA-3er 4 1.72 TAA-*** 0 0.00 TGA-*** 1 0.43 
TTG-Leu 4 1.72 TCG-Ser 4 1.72 TAG-*** 0 0.00 TGG-Trp 3 1.29 
CTT-Leu 3 1.29 CCT-Pro 6 2.58 CAT-His I 0.43 CGT-Arg 0 0.00 
CTC-Leu 4 1.72 CCC-Pro 4 1.72 CAC-His 1 0.43 CGC-Arg 0 0.00 
CTA-Leu 1 0.43 CCA-Pro 4 1.72 CAA-Gln 3 1.29 CGA-Arg 0 0.00 
CTG-Leu 2 0.86 CCG-Pro 1 0.43 CAG-Gin 4 1.72 CGG-Arg 0 0.00 
ATT-Ile 4 1.72 ACT-Thr 7 3.01 AAT-Asn 3 1.29 AGT-Ser 4 1.72 
ATC-Ile 5 2.15 ACC-Ttir 2 0.86 AAC-Asn 5 2.15 AGC-Ser 5 2.15 
ATA-Ile 0 0.00 ACA-Thr 11 4.74 AAA-Lys 9 3.87 AGA-Arg 1 0.43 
ATG-Het 3 1.29 ACG-Thr 8 3.44 AAG-Lys 9 3.87 AGG-Arg 2 0.86 
GTT-Val 2 0.86 GCT-Ala 4 1.72 GAT-Asp 5 2.15 GGT-Gly 8 3.44 
GTC-Val 8 3.44 GCC-Ala 5 2.15 GAC-Asp 5 2.15 GGC-Gly 1 0,43 
GTA-Val 2 0.86 GCA-Ala 7 3.01 &AA-Glu 4 1.72 GGA-Gly 5 2.15 
GTG-Val 5 2.15 GCG-Ala 4 1.72 GAG-Glu 7 3.01 GGG-Gly 6 2.58 
The full-length OP30 (without a His-tag and an EK site) gene is 696 bp with 232 
codons and 51.5% G+C content. 
Table 5- 5 Summary of codon usage in the modified P30 (MP30) 
Codon Count % Codon Count % Codon Count h Codon Count % 
TTT-Phe 3 1.29 TCT-Ser: 2 0.86 TAT-Tyr 0 0.00 TGT-Cys 0 0.00 
TTC-Phe 3 1.29 TCC-Ser 3 1.29 TAC-Tyr 3 1.29 TGC-Cys 11 4.74 
TTA-Leu 0 0.00 TCA-Sec 4 1.72 TAA-*** 0 0.00 TGA-*** 1 0.43 
TTG-Leu 4 1.72 TCG-Ser 0 0.00 TAG-*** 0 0.00 TGG-Trp 3 1.29 
CTT-Leu 3 1.29 CCT-Pro 6 2,58 CAT-His 0 0.00 CGT-Arg 0 0.00 
CTC-Leu 6 2.58 CCC-Pro 4 1.72 CAC-His 2 0.86 CGC-Arg 0 0.00 
CTA-Leu 0 0.00 CCA-Pro 4 1.72 CAA-Gln 3 1.29 CGA-Arg 0 0.00 
CTG-Leu 2 0.86 CCG-Pro 1 0.43 CAG-Gln 4 1.72 CGG-Arg 0 0.00 
ATT-Ile 4 1.72 ACT-Thr 8 3.44 AAT-J^sn 3 1.29 AGT-Ser 4 1.72 
ATC-Ile 5 2.15 ACC-Tlir 13 5.60 AAC-Asn 5 2.15 AGC-Ser 9 3.87 
ATA-Ile 0 0.00 ACA-Thr 7 3.01 AAA-Lys 9 3.87 AGA-Arg 1 0.43 
ATG-Het 3 1.29 ACG-Thn 0 0.00 AAG-Lys 9 3.87 AGG-Arg 2 0.36 
GTT-Val 9 3.87 GCT-Ala 12 5.17 GAT-Asp 8 3.44 GGT-Gly 7 3.01 
GTC-Val 0 0.00 GCC-Ala 9 3.87 GAC-Asp 2 0.86 GGC-Gly 4 1.72 
GTA-Val 0 0.00 GCA-Ala 0 0.00 GAA-Glu 3 �.29 GGA-Gly 8 3.44 
GTG-Val 8 3.44 GCG-Ala 0 0.00 GAG-Glu 8 3.44 GGG-Gly 0 0.00 




5 ' GGTACC GTCTAC 
AACA tTG GCT TTC ACT CTT AAG TGC CCT AAA ACC GCC CTC ACA 
GAG CCT CCC ACT CTT GCT TAG TCA CCC AAC AGG CAA ATC TGC 
CCA GCC GGT ACT ACC AGT AGC TGC ACA TCA AAG GCT GTG ACC 
TTG AGC TCC TTG ATT CCT GAA GCT GAA GAT AGC TGG TGG ACC 
GGC GAT TCT GCT AGT CTC GAC ACC GCT GGC ATC AAA CTC ACC 
GTT CCA ATC GAG AAG TTC CCC GTG ACA ACC CAG ACT TTT GTG 
GTT GGT TGC ATC AAG GGA GAT GAC GCT CAG AGT TGC ATG GTT 
ACC GTG ACA GTG CAA GCC AGA GCC TCA AGC GTT GTG AAT AAT 
GTT GCT AGG TGC TCC TAG GGT GCC GAT AGC ACT CTT GGT CCT 
GTT AAG TTG TCT GCC GAA GGA CCC ACT ACA ATG ACC CTC GTG 
TGC GGC AAA GAT GGA GTT AAA GTT CCT CAA GAT AAC AAT CAG 
TAG TGC TCC GGA ACC ACA CTG ACT GGT TGC AAC GAG AAG AGC 
TTC AAA GAT ATT TTG CCA AAA CTC ACT GAG AAC CCG TGG CAG 
GGT AAC GCT AGC AGT GAT AAG GGT GCC ACC CTC ACA ATC AAG 
AAA GAG GCT TTT CCA GCC GAG TCA AAA AGC GTT ATT ATT GGA 
TGC ACC GGC GGA AGC CCT GAG AAG CAC CAC TGC ACC GTG AAA 
CTG GAG TTT GCC GGA GCT GCT GGA TGA 
GTATAC GGATCC AAGCTT 3 ' 
AccI BamHI Hindlll 
Figure 5- 3 Nucleotide sequence of the modified P30 (MP30) synthetic gene 
The length of the MP30 gene (from start to stop codon) is 696 bp. 
Sixty-seven nucleotides (in red) were changed for codon optimization, 
representing 9.7% modification. Restriction sites (in italic) are 
present at the 5，(Kpnl and AccI) and 3' (AccI, BamHI and Hindlll) 
ends for subcloning purpose. A plant AUG context sequence 
(AACAATGG) is introduced (underlined) to enhance translation 
initiation. Sequence for amino acid Ala (GCT in bold) is added as 
the 2nd amino acid to stabilize the protein in cytosol. 
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5.2 Fusion of the P30 Gene with the LRP Gene 
Lysine-rich protein (LRP) is a seed protein from winged bean. It contains high 
lysine content with unknown biological function. According to Cheng (1999), the 
LRP protein could be expressed and stably accumulated at high level in the seed 
cytosol of transgenic Arabidopsis under the control of phaseolin regulatory 
sequences. The LRP gene itself may contain some protein-stabilizing signals that 
would be useful in enhancing the expression of the P30 gene in plants. To test and 
make use of these possible signals, we plan to fuse the P30 gene with the LRP gene. 
Secondary structure of LRP was first predicated from its coding sequence. 
The mid region of the polypeptide is of loose random coil conformation. The P30 
gene, with or without codon modification, will be inserted into this region to 
minimize its affect on the overall conformation of the fusion protein. Chimeric 
LRP-P30 genes regulated by the phaseolin promoter and terminator will be 
transformed into Arabidopsis for further expression analysis. 
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Chapter 6 Conclusion 
To test whether plants can be used as bioreactors to produce high quality T. 
gondii surface antigen P30 in bulk amount, the gene encoding this antigen, under the 
control of different promoters, had been introduced into model plant tobacco. 
Successful integration of transgenes into tobacco genome was confirmed by genomic 
PCR and Southern blot analysis. The P30 transcripts were also detected by 
RT-PCR and northern blot analysis of the P30 transformants. However, no 
recombinant P30 protein could be detected by SDS-PAGE and western blot analysis. 
Possible reasons for poor P30 expression in plants may be sited at translation and/ or 
post-translation levels. Two studies, focusing on improving translation efficiency 




Altenbach, S. B.，Pearson, K. W.，Meeker, G.，Staraci, L. C. and Sun, S. M. 1989. 
Enhancement of the methionine content of seed proteins by the expression of a 
chimeric gene encoding a methionine-rich protein in transgenic plants. Plant 
Molecular Biology 13: 513-22. 
Arakawa, T.，Chong, D. K.，Slattery, C. W. and Langridge, W. H. 1999. 
Improvements in human health through production of human milk proteins in 
transgenic food plants. Advances in Experimental Medicine & Biology 464: 
149-59. 
Baker, J. R. 1969. Toxoplasmea. Parasitic Protozoa 127-35. 
Biemans, R., Gregoire, D.，Haumont, M.’ Bosseloir，A., Garcia, L., Jacquet, A., 
Dubeaux, C. and Bollen, A. 1998. The conformation of purified Toxoplasma 
gondii SAGl antigen, secreted from engineered Pichia pastoris, is adequate for 
serorecognition and cell proliferation. Journal of Biotechnology 66: 137-46. 
Boothroyd, J. C., Hehl, A., Knoll, L. J. and Manger, I. D. 1998. The surface of 
Toxoplasma: more and less. International Journal for Parasitology 28: 3-9. 
Bourguin, I.，Chardes, T. and Bout, D. 1993. Oral Immunization with Toxoplasma 
gondii antigens in association with cholera toxin induces enhanced protective 
and cell-mediated immunity in C57BL/6 mice. Infection & Immunity 61: 
2082-8. 
Brinkmann, V.，Remington, J. S. and Sharma, S. D. 1993. Vaccination of mice 
with the protective F3G3 antigen of Toxoplasma gondii activates CD4+ but not 
CD8+ T cells and induces Toxoplasma specific IgG antibody. Molecular 
Immunology 30: 353-8. 
Bulow, R. and Boothroyd, J. C. 1991. Protection of mice from fatal Toxoplasma 
gondii infection by immunization with p30 antigen in liposomes. Journal of 
Immunology 147: 3496-500. 
119 
Burg, J. L., Perelman, D., Kasper, L. H.，Ware, P. L. and Boothroyd, J. C. 1988. 
Molecular analysis of the gene encoding the major surface antigen of Toxoplasma 
gondii. Journal of Immunology 141: 3584-91. 
Buxton, D. 1993. Toxoplasmosis: the first commercial vaccine. Parasitology 
Today 9: 335-7. 
Chen, X. G., Liu, G. Z.，Xu, F.，Wang, X. Z. and Jiang, J. B. 1994. Amplification, 
cloning, sequencing and expression of the gene encoding the major surface 
antigen of Toxoplasma gondii isolated in China. Journal of Medical College, 
PLA 9: 98-102. 
Chen, X. G.，Fung, M. C , Ma, X.，Peng, H. J., Shen, S. M. and Liu, G. Z. 1999. 
Baculovirus expression of the major surface antigen of Toxoplasma gondii and the 
immune response of mice injected with the recombinant P30. Southeast Asian 
Journal of Tropical Medicine & Public Health 30: 42-6. 
Chen, L. 2000. Transgenic manipulation of asparate family amino acid biosynthetic 
pathway in higher plants for improved plant nutrition. Ph. D. Dissertation. 
Department of Biology, The Chinese University of Hong Kong. 
Cheng, M. K. 1999. Transgenic expression of a chimeric gene encoding a 
lysine-rich protein in Arabidopsis. M. Phil. Dissertation. Department of 
Biology, The Chinese University of Hong Kong. 
Dalsgaard, K., Uttenthal, A., Jones, T. D.，Xu, F.，Merryweather, A., Hamilton, W. 
D., Langeveld, J. P., Boshuizen, R. S., Kamstrup, S., Lomonossoff, G. P., Porta, 
C., Vela, C , Casal, J. I., Meloen, R. H. and Rodgers, P. B. 1997. Plant-derived 
vaccine protects target animals against a viral disease. Nature Biotechnology 15: 
248-52. 
Doyle, J. D.，Doyle, J. L. and Bailey, L. H. 1990. Isolation of plant DNA from 
fresh tissue. Focus 12: 13-5. 
Dubey, J. P. 1996. Strategies to reduce transmission of Toxoplasma gondii to 
animals and humans. Veterinary Parasitology 64: 65-70. 
120 
Dubey, J. P., Lindsay, D. S. and Speer, C. A. 1998. Structure of Toxoplasma gondii 
tachyzoites, bradyzoites, and sporozoites and biology and development of tissue 
cysts. Clinical Microbiology Reviews 11: 267-99. 
Fischer, R., Drossard, J., Commandeur, U., Schillberg, S. and Emans, N. 1999. 
Towards molecular farming in the future: moving from diagnostic protein and 
antibody production in microbes to plants. Biotechnology <Sc Applied 
Biochemistry 30: 101-8. 
Fischer, R. and Emans, N. 2000. Molecular farming of pharmaceutical proteins. 
Transgenic Research 9: 279-99. 
Frenkel, J. K., Dubey, J. P. and Miller, N. L. 1970. Toxoplasma gondii in cats: 
fecal stages identified as coccidian oocytes. Science 167: 893-6. 
Frenkel, J. K. 1988. Pathophysiology of toxoplasmosis. Parasitology Today 4: 
273-8. 
Frigerio, L., De Virgilio, M., Prada, A., Faoro, F. and Vitale, A. 1998. Sorting of 
phaseolin to the vacuole is saturable and requires a short C-terminal peptide. 
Plant Cells 10: 1031-42. 
Frigerio, L.，Foresti, 0 ” Felipe, D. H.，Neuhaus, J.-M. and Vitale, A. 2001. The 
C-terminal tetrapeptide of phaseolin is sufficient to target green fluorescent 
protein to the vacuole. Journal of Plant Physiology 158: 499-503. 
Gross，U. and Pohl, F. 1996. Influence of antimicrobial agents on replication and 
stage conversion of Toxoplasma gondii. Current Topics in Microbiology and 
Immunology 219: 235-45. 
Guerineau, F., Lucy, A. and Mullineaux, P. 1992. Effect of two consensus 
sequences preceding the translation initiator codon on gene expression in plant 
protoplasts. Plant Molecular Biology 18:815-8. 
121 
Haming, D., Spenter, J., Metsis, A., Vuust, J. and Petersen, E. 1996. Recombinant 
Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is 
recognized by human Toxopiasma-specific immunoglobulin M (IgM) and IgG 
antibodies. Clinical and Diagnostic Laboratory Immunology 3: 355-7. 
Hoffman, L. M.，Donaldson, D. D. and Herman, E. M. 1988. A modified storage 
protein is synthesized, processed, and degraded in the seeds of transgenic plants. 
Plant Molecular Biology 11:717-29. 
Horsch, R. B., Fry, J. E., Hoffmann, N. L., Eichholtz, D.，Rogers, S. G. and Fraley, R. 
T. 1985. A simple and general method for transferring genes into plants. 
Science 111: 1229-31. 
Ikemura, T. 1982. Correlation between the abundance of yeast transfer RNAs and 
the occurrence of the respective codons in protein genes. Differences in 
synonymous codon choice patterns of yeast and Escherichia coli with reference to 
the abundance of isoaccepting transfer RNAs. Journal of Molecular Biology 158: 
573-97. 
Jackson, M. H. and Hutchison, W. M. 1989. The prevalence and source of 
Toxoplasma infection in the environment. Advances in Parasitology 28: 55-105. 
Jefferson, R. A., Kavanagh, T. A. and Bevan, M. W. 1987. GUS fusions: 
b-glucuronidase as a sensitive and versatile gene fusion marker in higher plants. 
EMBO Journal 6: 3901-7. 
Johnson, A. M., McDonald, P. J. and Neoh, S. H. 1983. Monoclonal antibodies to 
Toxoplasma cell membrane surface antigens protect mice from toxoplasmosis. 
Journal of Protozoology 30: 351-6. 
Jones, H. 1995. Gene transfer into plant protoplasts by electroporation. Methods 
in Molecular Biology 49: 107-12. 
Kasper, L. H., Crabb, J. H. and Pfefferkom, E. R. 1983. Purification of a major 
membrane protein of Toxoplasma gondii by immunoabsorption with a 
monoclonal antibody. Journal of Immunology 130: 2407-12. 
122 
Kasper, L. H.，Bradley, M. S. and Pfefferkom, E. R. 1984. Identification of 
stage-specific sporozoite antigens of Toxoplasma gondii by monoclonal 
antibodies. Journal of Immunology 132: 443-9. 
Kasper, L. H. and Boothroyd, J. C. 1993. Toxoplasma gondii and toxoplasmosis. 
Immunology and Molecular Biology of Parasitic Infections 269-301. 
Kasper, L. H. and Khan, 1. A. 1993. Role of P30 in host immunity and 
pathogenesis of T. gondii infection. Research in Immunology 144: 45-8. 
Khan, I. A.，Eckel, M. E.，Pfefferkom, E. R. and Kasper, L. H. 1988. Production of 
gamma interferon by cultured human lymphocytes stimulated with a purified 
membrane protein (P30) from Toxoplasma gondii. Journal of Infectious 
Diseases 157: 979-84. 
Kim, K., Bulow, R., Kampmeier, J. and Boothroyd, J. C. 1994. Conformationally 
appropriate expression of the Toxoplasma antigen SAGl (p30) in CHO cells. 
Infection <Sc Immunity 62: 203-9. 
Lin, J. J., Nacyra, A. G. and Kuo, J. 1994. Effects of Agrobacterium cell 
concentration on the transformation efficiency of tobacco and Arabidopsis 
thaliana. Focus 16: 72-7. 
Lunden, A.，Lovgren, K., Uggla, A. and Araujo, F. G. 1993. Immune responses and 
resistance to Toxoplasma gondii in mice immunized with antigens of the parasite 
incorporated into immunostimulating complexes. Infection & Immunity 61: 
2639-43. 
Mason, H. S., Lam, D. M. and Amtzen, C. J. 1992. Expression of hepatitis B 
surface antigen in transgenic plants. Proceedings of the National Academy of 
Sciences of the United States ofAmerica 89: 11745-9. 
Mason, H. S., Ball, J. M., Shi, J. J., Jiang, X., Estes, M. K. and Amtzen, C. J. 1996. 
Expression of Norwalk virus capsid protein in transgenic tobacco and potato and 
its oral immunogenicity in mice. Proceedings of the National Academy of 
Sciences of the United States of America 93: 5335-40. 
123 
McLeod, R.，Frenkel, J. K., Estes, R. G.，Mack, D. G.，Eisenhauer, P. B. and Gibori, 
G. 1988. Subcutaneous and intestinal vaccination with tachyzoites of 
Toxoplasma gondii and acquisition of immunity to peroral and congenital 
Toxoplasma challenge. Journal of Immunity 140: 1632-7. 
Meyer, P. and Saedler, H. 1996. Homology-dependent gene silencing in plants. 
Annual Review of Plant Physiology and Plant Molecular Biology 47: 23-48. 
Negrutiu, I., Shillito, R.，Potrykus, L, Biasini，G. and Sala, F. 1987. Hybrid genes 
in the analysis of transformation conditions. Setting up a simple method for 
direct gene transfer in plant protoplasts. Plant Molecular Biology 8: 363-73. 
Partanen, P., Turunen, H. J.，Paasivuo, R. T. A. and Leinikki, P. O. 1984. 
Immunoblot analysis of Toxoplasma gondii antigens by human immunoglobulins 
G, M and A antibodies at different stages of infection. Journal of Clinical 
Microbiology 20: 133-135. 
Prols, F. and Meyer, P. 1992. The methylation patterns of chromosomal integration 
regions influence gene activity of transferred DNA in Petunia hybrida. Plant 
Journal 2: 465-75. 
Rouwendal, G. J. A., Mendes, O. and Douwe de Boer, A. 1997. Enhanced 
expression in tobacco of the gene encoding green fluorescent protein by 
modification of its codon usage. Plant Molecular Biology 33: 989-99. 
Santoro, F., Afchain, D., Pierce，R.，Cesbron, J. Y.，Ovlaque, G. and Capron, A. 1985. 
Serodiagnosis of toxoplasma infection using a purified parasite protein (P30). 
Clinical & Experimental Immunology 62: 262-9. 
Sciammarella, J. 2001. Toxoplasmosis from emergency medicine/infectious 
diseases. (Internet Source) 
Seki, M., Komeda, Y., lida, A.，Yamada, Y. and Morikawa, H. 1991a. Transient 
expression of beta-glucuronidase in Arabidopsis thaliana leaves and roots and 
Brassica napus stems using a pneumatic particle gun. Plant Molecular Biology 
17: 259-63. 
124 
Seki, M” Shigemoto, N.，Komeda, Y.，Imamura, J. and Morikawa, H. 1991b. 
Transgenic Arabidopsis thaliana plants obtained by particle bombardment 
mediated transformation. Applied Microbiology and Biotechnology 28: 228-30. 
Sharma, S. D., Araujo, F. G. and Remington, J. S. 1984. Toxoplasma antigen 
isolated by affinity chromatography with monoclonal antibody protects mice 
against lethal infection with Toxoplasma gondii. Journal of Immunity 133: 
2818-20. 
Sibley, L. D” Krahenbuhl, J. L., Adams, G. M. and Weidner, E. 1986. Toxoplasma 
modifies macrophage phagosomes by secretion of a vesicular network rich in 
surface proteins. Journal of Cell Biology 103: 867-74. 
Sun, S. M., Mutschler, M. A., Bliss, F. A. and Hall, T. C. 1978. Protein synthesis 
and accumulation in bean cotyledons during growth. Plant Physiology 61: 
918-23. 
Sun, S. M., Slightom, J. L. and Hall, T. C. 1981. Intervening sequences in a plant 
gene - comparison of the partial sequence of cDNA and genomic DNA of French 
bean phaseolin. Nature 289: 37-41. 
Tomavo, S.，Dubremetz, J. F. and Schwarz, R. T. 1992. A family of glycolipids 
from Toxoplasma gondii. Identification of candidate glycolipid precursor(s) for 
Toxoplasma gondii glycosylphosphatidylinositol membrane anchors. Journal of 
Biological Chemistry 267: 11721-8. 
Tomavo, S. 1996. The major surface proteins of Toxoplasma gondii: structures and 
functions. Current Topics in Microbiology and Immunology 219: 45-53. 
Tso, T. C. 1972. Tobacco plant and tobacco types. Physiology and Biochemistry 
of Tobacco Plants 3-8. 
Varshavsky, A. 1997. The N-end rule pathway of protein degradation. Genes to 
Cells 2: 13-28. 
125 
Vaucheret, H., Beclin, C” Elmayan, T.，Feuerbach, F.，Godon, C.，Morel, J. B.， 
Mourrain, P., Palauqui, J. C. and Vemhettes, S. 1998. Transgene-induced gene 
silencing in plants. Plant Journal 16: 651-9. 
Ware, P. L. and Kasper, L. H. 1987. Strain-specific antigens of Toxoplasma gondii. 
Infection & Immunity 55: 778-83. 
Wong, S. Y. and Remington, J. S. 1994. Toxoplasmosis in pregnancy. Clinical 
Infectious Diseases 18: 853-61. 
Yanofsky, C. 1981. Attenuation in the control of expression of bacterial operons. 
Nature 289: 751-8. 
Zenner，L., Estaquier, J., Darcy, F., Maes, P., Capron, A. and Cesbron-Delauw, M. F. 
1999. Protective immunity in the rat model of congenital toxoplasmosis and the 
potential of excreted-secreted antigens as vaccine components. Parasite 
Immunology 21: 261-72. 
126 
• 巧 1 〒、广 、： ‘ : .—I 
^ - r r 二 ‘ 、 ： . . • -：：, '> 
S • • 
敎J, 丨，‘、 
CUHK L i b r a r i e s 
DD3fl71flST 
